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Abstract
Introduction: Since Human Immunodeficiency Virus (HIV)-1 was determined to be the
etiological agent behind acquired immunodeficiency syndrome (AIDS) in 1983, numerous
attempts at a cure have been made; however, none have been effective. One of the primary
roadblocks in achieving a cure is a transcriptionally-silent latent reservoir of memory CD4+ T
cells harboring HIV provirus. Combined antiretroviral therapy (cART) inhibits actively
replicating virus by interfering with various stages of the replication cycle. Therefore, nonreplicative viruses–like the proviruses found in latently infected cells–are hidden from the
actions of continued antiretroviral therapy. As a result, cART discontinuation or treatment
holidays can result in rapid viral recrudescence within days to weeks. It is thought that
latency is established when HIV infects CD4 T cells that are transitioning from effector to
memory status, which effectively traps the virus in an environment that is not conducive to
replication due to the low metabolic activity characteristic of these cells at G0. During latency
reversal, it is believed that the provirus undergoes transcriptional reactivation, allowing HIV1 to replicate and produce infectious progeny virus that can be targeted by cART. However, a
significant hurdle against the development of a vaccine against HIV is the immense viral
diversity within each infected individual. A vaccine preparation should therefore encompass
a near-complete repertoire of viral quasispecies to increase antigen coverage for maximal
reactivation. Based on this, our group has developed a genetically diverse virus-like particle
(VLP)-based vaccine, which is thought to be capable of activating a diverse array of cognate
HIV-specific CD4+ T cells. These VLPs are morphologically and enzymatically identical to
wild-type HIV-1; however, it contains several mutations that abrogate reverse transcription,
integration, and viral RNA packaging.
Methodology: Antigenicity of virus particles (VP) and VLPs were determined as a function
of i) TNFα secretion measured in cell culture supernatant of HIV– peripheral blood
mononuclear cells (PBMC) and ii) NF-κB and interferon regulatory factor (IRF) activation.
Following an ex vivo DC-T cell co-culture assay, induced HIV RNA from recrudescent virus
was quantified in cell culture supernatants following latency reversal and using an in-house
developed qRT-PCR assay specific for the 5’ region of HIV RNA. In addition, T cell
activation was measured as a function of IFN-γ secretion using a commercially available
ELISpot kit. To determine if immunostimulatory RNA could be preferentially packaged into
VLP, 293T cells were co-transfected with a VLP-encoding plasmid and immunostimulatory
RNA-encoding plasmid. The adjuvanted VLPs were then concentrated by a combination of
filtration and ultra-centrifugation before purified VLPs were assayed for p24 and RNA
content. Immunostimulatory potential of these RNA were measured as a function of NF-κB
and IRF activation in THP-1 cells, and TNF-α and IFN-α secretion in HIV– PBMC.
Results: VPs induced greater TNFα secretion than VLPs in HIV– PBMC, supporting
observations of VPs inducing greater increases in NF-κB and IRF activation compared to
VLP. In addition, these VPs induced greater latency reversal in HIV+ PBMC, as a function of
increased CD4+ T cell activation and increased HIV RNA in culture supernatant following
latency reversal. We therefore engineered immunostimulatory RNA that can be packaged
i

into VLPs and found that these RNAs augmented VLP antigenicity in PBMC and THP-1
cells in a manner that was dependent on RNA recognition by intracellular pattern recognition
receptors.

Lay Summary: Since Human Immunodeficiency Virus (HIV)-1 was determined to be the
etiological agent behind acquired immunodeficiency syndrome (AIDS) in 1983, numerous
attempts at a cure have been made; however, none have been effective. One of the primary
roadblocks in achieving a cure is a transcriptionally-silent latent reservoir of memory CD4+
T cells harboring HIV provirus. Combined antiretroviral therapy (cART) inhibits actively
replicating virus by interfering with various stages of the replication cycle. Therefore, nonreplicative viruses–like the proviruses found in latently infected cells–are hidden from the
actions of continued antiretroviral therapy. As a result, cART discontinuation or treatment
holidays can result in rapid viral recrudescence within days to weeks. Our group has
developed a genetically diverse virus-like particle (VLP)-based vaccine, which is thought to
be capable of activating this reservoir. These VLPs are morphologically and enzymatically
identical to wild-type HIV-1; however, it contains several mutations that abrogate reverse
transcription, integration, and viral RNA packaging. In this thesis, we show that virally
packaged RNA within these particles can augment VLP antigenicity and latency reversal.
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Chapter 1 – Introduction

1.1 Macroscopic Characteristics of HIV-1
1.1.1 The History of HIV
In 1984, a seminal study was published that implicated Human Immunodeficiency Virus
1 (HIV-1)–originally characterized as Human T Lymphotropic Virus III (HTLV-III)–as
the etiological agent of acquired immunodeficiency syndrome (AIDS)1. Just a year
before, Montagnier and his group isolated the virus from a patient at risk of AIDS, and
was subsequently awarded the Nobel prize in Physiology and Medicine for their findings
in 2008 2,3. The earliest documented case of HIV infection traces back to a preserved
plasma sample originating from a man living in the Belgian Congo city of Leopoldville in
19594. It is here that the first zoonotic transmission of a simian immunodeficiency viruses
(SIV) into the human population, from non-human primates, is thought to have occurred5.
There are over 40 different SIV strains that are endemic to non-human primate
populations6. Therefore, the most plausible cause for these cross-over events stem from
humans encountering contaminated blood or tissues from infected animals. The local
practices of hunting and butchering primates for bushmeat therefore offers the most
reasonable antecedent7. The reason behind the emergence of HIV as a pandemic agent of
disease lay within the demographic data of Leopoldville in 1959. Urban city centers, like
Leopoldville, in west central Africa underwent unprecedented levels of urban expansion
in the 1960s and corresponded with significant movements of human populations8. At the
time, Leopoldville was the largest city center in the region, and had several major routes
of travel and commerce. This is believed to have been a significant driving force behind
the stealthy dissemination of the virus across the globe. In 1984, across the Atlantic
Ocean, an increasing number of men who have sex with men (MSM) in America were
beginning to suffer from symptoms of an immune deficiency disorder, characterized by
defective T cell immunity. The immune deficiency disorder among MSM populations
was subsequently named gay-related immune deficiency (GRID)9. However, later that
same year, HIV was identified as the etiological agent behind the enigmatic
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immunodeficiency disorders. Phylogenetic analyses of HIV sequences from across the
globe revealed four distinct HIV lineages: M, N, O, and P, each of which was a product
of an independent cross-species transmission event of SIV into humans10.

1.1.2 The Global Diversity of the HIV Pandemic
Three out of the four lineages of HIV, group N, O, and P, have not disseminated across the
globe, but are instead rare, and localized to certain west and central African countries, such
as Gabon and Cameroon6. However, the pandemic group M lineage that originated from
Leopoldville, continues to dominate world-wide infections. As the virus encountered
different human populations in distinct geographical areas, independent genetic
bottlenecks–termed founder events–were initiated. This is in part, due to the diverse
selective pressures exerted by the recipient tissue and transmission fluid11. As a result of
these factors, coupled with the high error rate of the viral RNA-dependent DNA
polymerase and high viral turnover12,13, nine genetically distinct subtypes (A-D, F-H, J,
and K) appeared across the globe14. Africa, the epicenter of infection, holds the greatest
viral genetic diversity. Subtype C predominates in southern Africa15,16, whereas subtype A
predominates in eastern Africa while subtypes C and D occasionally co-circulate17,18. West
and central Africa are inundated with several circulating recombinant forms (CRF) of the
virus19. In North America, Europe, and Australia, subtype B predominates20–22. Likewise,
in South America, subtype B predominates; however, there has been recent increases in
subtype C infections23. Asia has been described as a hotbed for the emergence of
recombinant viral strains. In fact, there are more CRFs identified in China than any other
country in the world24. While these CRFs predominate eastern and southeastern Asia,
subtype A is prevalent in Russia and other countries that were formally part of the Soviet
Union25. In south Asian countries, subtype C is found to predominate26. On a global scale,
subtype C represents approximately 46.6% of infections, whereas subtypes A and B
represent approximately 10.2% and 12.1%, respectively27.

1.1.3 HIV Transmission Routes
Nearly 70% of HIV-1 transmission events occur during heterosexual intercourse as a result
of contacting semen and/or blood from infected individuals28. The other 30% of
transmission events mostly correspond to three alternate transmission routes. The first of
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which is encountering contaminated rectal fluids during anal intercourse amongst MSM
populations. Secondly, vertical transmission of the virus from mother to infant in utero, or
through contact with breastmilk from infected mothers. Thirdly, direct intravenous
inoculation of live HIV from infected individuals can be facilitated by needle sharing
practices amongst populations of intravenous drug users29.

1.2 Microscopic Properties of HIV-1
1.2.1 The Structure and Genomic Organization of HIV-1
HIV-1 belongs to the Retroviridae family and is a member of the Lentivirinae genus. Viral
particles are spherical, enveloped, and are 80-120 nm in diameter30. The viral genome is
comprised of two copies of single-stranded, 9.7 kb positive-sense RNAs. Like all viruses
in family Retroviridae, HIV genomic RNA encodes three canonical polyproteins: Gag, Pol,
and Env31. The gag gene is responsible for encoding structural proteins like matrix (MA,
p17), capsid (CA, p24)32, and a smaller nucleocapsid protein (p7), the latter aiding in viral
genomic stability33. The pol gene encodes the reverse transcriptase (RT, p51), RNase H
(p15), and integrase (INT, p32). The env gene is responsible for encoding the envelope
docking (gp120) and transmembrane (gp41) glycoproteins34. Despite the limited coding
capacity due to the relatively small size of the viral genome, alternative RNA splicing and
overlapping reading frames allow the virus to produce six additional accessory proteins:
Tat, Rev, Nef, Vif, Vpr, Vpu (Fig 1). These accessory proteins alter the host cell
environment to favor viral persistence, replication, and transmission35. The host-derived
envelope is studded with viral glycoproteins that facilitate adsorption and entry into host
cells. These glycoproteins exist as trimeric complexes of gp41 and gp120 36. Below the
host-derived lipid envelope lies two proteinaceous capsids–p17 and p24–both originating
from the Gag polyprotein. A polymeric matrix of p17, lies directly underneath the lipid
envelope, and offers structural rigidity and integrity, whereas the viral genome is packaged
and protected within the p2437. Multiple p7 proteins stud the viral genome. The DNAbinding capability of p7 conferred by a basic tract of zinc-finger motifs is suggested to play
a significant role in the affinity of p7 to RNA38.
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Figure 1. Genomic Structure of HIV
Three reading frames encode three canonical retroviral proteins: Gag, Pol, Env. Six
accessory proteins are also encoded within the genome: Tat, Rev, Nef, Vif, Vpr, and Vpu.
The genome is flanked by two long terminal repeats (LTR).

Propagation of infectious HIV depends on its ability to preferentially package viral
genomic RNA over the larger pool of existing mRNAs in the cellular milieu39.To achieve
this, a cis-acting packaging signal (Ψ), located within the 5’ untranslated region of HIV
RNA, facilitates binding of HIV RNA to Gag and efficiently nucleates particle formation40.
The Ψ contains extensive secondary structure that enables the binding of multiple Gag
molecules facilitating Gag molecule clustering and the subsequent stabilization of Gag–
Gag homotypic interactions41. In contrast, RNA species lacking Ψ are severely limited in
facilitating the accretion of Gag–a key requirement for nucleating virus particle
formation39. The viral genome is flanked by regions encoding two long terminal repeats
(LTR), which among other functions, enables the virus to integrate into the host cell
genome as a provirus42–44. Although the LTRs contain three physical regions: U3, R, and
U5, there are four regions that regulate transcription within the LTR. Three of these
regulatory regions are in U3, and the remaining is in R. Each of these functional domains
are responsible for regulating viral transcription following integration45. The
transactivation response (TAR) element within R interacts with the HIV accessory protein,
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Tat to promote viral mRNA production46. The basal/core promotor, core enhancer, and
modulatory regions are found in U3 and collectively bind to a myriad of cellular
transcription factors. Therefore, once integrated, the 5’ LTR acts as a promotor for the
provirus and is responsible for recruiting and binding cellular transcription factors like
nuclear factor κB (NF-κB), nuclear factor of activated T cells (NFAT), and activator
protein 1 (AP-1), to mediate proviral transcription47. In contrast, the 3’ LTR plays less of
a role in transcriptional initiation due to interference with 5’ LTR transcription, but rather
aids in the polyadenylation of viral transcripts48.

1.2.2 Mechanism of HIV Infection
HIV has a cellular tropism for activated CD4+ T cells. This is due to the propensity of
activated T cells to upregulate CCR5 and CXCR4, which —in concert with host CD4
receptors and viral gp120—facilitates viral entry49,50. During the early stages of mucosal
infection, the diverse swarm of viral quasi-species deposited within the host experiences a
significant genetic bottleneck prior to establishing systemic infection. A study comparing
the HIV envelope sequence diversity within the female reproductive tract and matched
plasma samples from a cohort of acutely infected Zimbabwean and Ugandan women,
showed disproportionate counts of distinct viral clones within the endocervix compared to
matched plasma samples51. In particular, the viral sequence diversity within the endocervix
was significantly higher than the sequence diversity of viral clones found in plasma. This
suggests that the combination of physical and immunological constraints within the
mucosa acts as a genetic sieve, resulting in the establishment of a genetically homogenous
systemic infection (Fig 2).
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Figure 2. Genetic sieve effect for mucosal HIV transmission
The diverse swarm of viral quasi-species deposited into host mucosa undergoes a
significant genetic contraction, resulting in a relatively clonal virus population that
disseminates and establishes infection.

In support of this notion, studies conducted in non-human primate (NHP) models of
infection using atraumatic inoculation of SIV into the vaginal mucosa, have shown a single
viral genetic variant, termed the transmitter/founder (TF) viruses, that can preferentially
cross the epithelial barrier and establish multiple localized foci of infection within a
population of cells52. These NHP models have also shown that 63% of early cellular targets
for infection are CCR6+ CD4+ T cells expressing high levels of RORγT transcription factor,
which is highly expressed in TH17 cells within the mucosa. In addition, 12% of early
cellular targets constitute other CD4+ T cells, whereas the remaining 25% of cellular targets
were non-T cells that were either CCR6+, corresponding to immature dendritic cells (DC),
or non-T cells that were CCR6‒, corresponding to macrophages52. Therefore, TH17 cells
are preferentially infected and depleted during the eclipse stages of infection in NHPs.
Several lines of evidence suggest that TH17 cells are critical for maintaining mucosal
barrier integrity53. Therefore, the depletion of these cells lends itself towards a reduction in
barrier integrity, thereby encouraging viral penetration, replication, and dissemination. In
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addition to this, there are several other mechanisms that reduce barrier integrity. For
instance the interaction of HIV gp120 and Tat with the mucosal epithelia results in the
disruption of epithelial tight junctions, which further deteriorates mucosal barrier
function54–56. Substantial evidence indicates gp120 and Tat aberrantly activate mitogenactivated protein kinase (MAPK) cascades, resulting in the deterioration of tight junction
integrity achieved by tight junction protein internalization and proteasomal degradation57–
59

.

HIV infection is characterized by the continuous depletion of CD4+ T cells, which play an
important role in developing adaptive immunity against pathogenic infections60. However
as demonstrated with TH17 cells, not all CD4+ T cell subsets are depleted equally. HIV
preferentially infects activated CD4+ T cells over their naïve counterparts61. Extensive
studies have shown that the depletion of T cells is primarily mediated through apoptotic
and pyroptotic mechanisms as opposed to consequences of viral cytopathic effects62.
Furthermore, evidence suggests that majority of CD4+ T cell death occurs in uninfected
bystander cells. Bystander cell death accounts for ~ 95% of the CD4+ T cell depletion,
wherein viral replication is rendered abortive due to the quiescent state of these cells. As a
result, accumulation of incomplete reverse transcripts is recognized by DNA sensor IFI16,
resulting in caspase-1 inflammasome assembly and subsequent cell pyroptosis62. During
pyroptosis, cytoplasmic contents and pro-inflammatory cytokines like IL-1β are released
into the extracellular milieu, resulting in a highly inflammatory environment that attracts
more target CD4+ T cells63. However, in the 5% of activated permissive cells, productive
infection induces activation of caspase-3 and subsequent cell death through apoptosis.
Therefore, it is apparent that the main driving force behind CD4+ T cell depletion is
mediated by caspase-1 mediated pyroptosis62. Remarkably within lymph nodes of infected
individuals, molecular signatures of apoptosis are readily apparent in the paracortical
zones, which is rich in resting CD4+ T cells. The ongoing pro-inflammatory environment
imbued by apoptosis of bystander cells within this anatomical compartment contributes to
a positive feedback loop that recruits more activated T cells and fuels CD4+ T cell
depletion60,63,64.
Entry into susceptible host cells require cognate recognition of viral Env with CD4, the
latter of which is found in abundance on the cell surface of T lymphocytes. Env gp120
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contains a CD4 binding site (CD4bs), which enables Env to interact with CD4+ T cells65.
This binding interaction induces a localized conformational change within gp120, allowing
binding of an entry co-receptor, either CXCR4 (X4) or CCR5 (R5). This differential coreceptor usage gives rise to X4- or R5-tropic viruses. Once a co-receptor is bound, the
gp120 trimer undergoes a dramatic conformational change, exposing a hydrophobic gp41
fusion peptide that penetrates and tethers viral particles to the host cell membrane66. The
potential energy released as a result of this conformational change drives the formation of
a six-helix bundle that brings the viral envelope and host cell membrane in close apposition
until a fusion pore is created, and the viral core is deposited into the cytoplasm65. The viral
core consists of approximately 1500 monomers of p24 capsid proteins67. N-terminal
domain interactions between capsid proteins form 250 rigid hexagonal structures that are
linked to each other through C-terminal domain interactions. As a result of these Nterminal domain interactions and C-terminal domain interactions, hexagonal lattice
structures are generated, which are juxtaposed to create a unique fullerene cone. The poles
of the cone are capped by 7 pentameric rings at the wide end, and 5 pentameric rings at the
narrow end68. There are three models that describe the uncoating process of the viral capsid.
In the first model, the capsid is uncoated immediately after viral capsid deposition into the
cytoplasm. Evidence for this model suggest that virions contain high concentrations of
capsid protein to ensure the metastability of the viral core. Capsid metastability refers to
the equilibrium between capsid stability and instability, the former of which protects the
genome, and the latter required for depositing viral RNA into the host cell. As a result of
the drastic change in the concentration of free capsid protein in the cytoplasm, the core
begins to disintegrate as the concentration of free capsid protein is too low to maintain the
metastable integrity of the viral core69. The second model proposes that the viral core
remains intact for some time after deposition into the cytoplasm. In this model, uncoating
occurs gradually as the viral core is trafficked towards the nucleus and reverse transcription
is initiated. This model hypothesizes that as the core is transported to the nucleus, several
conformational rearrangements within the capsid protein trigger uncoating. Evidence
suggests that these molecular rearrangements are induced by three independent factors:
changes in the colligative properties of intracellular milieus between different intracellular
compartments, interaction with various cellular factors, and molecular rearrangements that
accompany reverse transcription70. In support of this model, it has been shown that viral
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cores in the cytoplasm attain different sizes and shapes compared to mature extracellular
cores. The broad morphological spectrum encompassed by viral cores within the cell is
thought to correspond to complex molecular transformations as the core is transported to
the nucleus71. However, these morphological changes may be accounted for by variations
in preparation and isolation protocols and therefore, must be taken into consideration. The
third, and most popular model, predicts a late uncoating event since reverse transcriptase
is maintained at a high stoichiometric ratio to the viral genome within the core, which
offsets the tendency of reverse transcriptase to dissociate from its template. This model
suggests late uncoating because the dilution of reverse transcriptase in the cytoplasm would
reduce the stoichiometric ratio of reverse transcriptase to its template, resulting in
inefficient reverse transcription70,72. Inter-ring spaces within the viral core are 10 nm in
size and permits the entry of non-limiting deoxyribonucleotides within the cytoplasm into
the viral core, facilitating reverse transcription.
Like other DNA polymerases, reverse transcriptase requires a primer and template to
initiate polymerization. A host-derived tRNA, usually Lys3, captured within the viral core
during particle synthesis mediates priming for reverse transcriptase73. The tRNA binds to
a 5’ region, 182 bp downstream of the 5’ end of the RNA genome, called primer binding
site (PBS), which enables the initiation of reverse transcription. Reverse transcriptase
catalyzes DNA synthesis and reaches the 5’ end of the genome after synthesizing a minusstrand strong stop cDNA ((–) ssDNA), which is 181 bp in length. Concomitantly, RNase
H, which is a catalytic domain within reverse transcriptase, degrades viral RNA in the
context of RNA-DNA duplexes. In a subsequent (–) ssDNA strand transfer event, the (–)
ssDNA dissociates and interacts with the 3’ end of the LTR through complementary basepairing. Two polypurine tracts (PTT) within the viral RNA – namely the central PPT
(cPPT) and 3’ PPT – resist degradation by RNase H and serve as primers for plus (+)strand synthesis. This is a unique property of viruses within genus Lentiviridae in that (+)strand DNA synthesis is primed at two independent locations within the viral genomic
RNA. That is, the primary upstream site of extension is primed by Lys3 tRNA binding to
PBS, whereas the secondary downstream site of extension is primed by the 3’ PPT. As a
result of this phenomenon, as the downstream (+)-strand DNA is displaced by upstream
(+)-strand DNA during strand displacement synthesis, a central DNA flap that is 99-
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nucleotides long is generated. Importantly, several studies show the importance of the
central DNA flap as a cis-determinant for core disassembly and nuclear import. In support
of this, several studies show that inhibiting reverse transcription or abrogating central DNA
flap formation, leads to an accumulation of viral cores at the nuclear membrane that contain
the viral genome. This suggests that viral core uncoating is dependent on the completion
of reverse transcription and offers evidence that challenge the notion of progressive viral
core uncoating70. Therefore, uncoating is not triggered until reverse transcription is
completed, and the viral core has trafficked to the nuclear pore. Once this occurs, several
cellular and viral proteins interact with the dsDNA molecule to form the karyophilic preintegration complex (PIC), capable of facilitating the transport of the viral genome into the
nucleus (Fig 3). Although capsid protein is not detected in the PIC, the presence of other
viral proteins such as MA is a subject of contention. However, it is known these PICs
contain virally encoded INT and host-derived proteins that facilitate the import of the PIC
into the nucleus in an energy-dependent manner74. Viral CA interacts with host RANBP2
to facilitate docking of the viral core to the cytoplasmic face of nuclear pore complex,
which further supports the hypothesis that viral uncoating is not triggered until the viral
core has trafficked to the nuclear pore75. Virally encoded Vpr contains a non-canonical
nuclear localization signal (NLS), allowing the import of Vpr into the nucleus through
importin-α-dependent pathways. Here, Vpr interacts with nucleoporins within the
nucleoplasmic face of the nuclear pore complex, such as NUP153, to facilitate viral core
binding.
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Figure 3. Nuclear import of HIV PIC through nuclear pore complexes
The HIV PIC is imported into the nucleus in a manner dependent on both cellular and viral
proteins. Once in the nucleus, the PIC mediates proviral integration into host genome.

In addition, host cleavage and polyadenylation specificity factor 6 (CPSF6) has been shown
to interact with viral CA protein, and import RNA splicing machinery into the nucleus76,77.
Importantly, CPSF6 plays a critical role in targeting viral integration into highly expressed
genes within open chromatin (euchromatin) areas of the chromosomes. In loss-of-function
studies, that mutate the viral CA protein to diminish its binding affinity for CPSF6, the PIC
enters the nucleus through alternative mechanisms that are not well characterized and
integrates into transcriptionally repressed regions of chromatin. In fact, this mutant has
been shown to become insensitive to knockdowns in RANBP2 and NUP153. Therefore, it
is suggested that CPSF6 promote entry of the PIC into the nucleus through import
mechanisms that rely on RANBP2 and NUP153 and plays an important role in targeting
the integration of viral genomes into euchromatin.
Once the PIC enters the nucleus, for reasons that are not clear, over 85% of PICs are
believed to not integrate into the host genome78. Due to the inverted LTRs, the viral DNA
can auto-integrate and produce a variety of circular structures. In addition, host double-
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strand break repair systems, such as nonhomologous end-joining, detects the dsDNA and
generates 2’ LTR circles to decrease the amount of free DNA ends within the cell, which
in turn subverts cellular apoptotic responses to double-stranded breaks79,80. In the
remaining cases, the viral DNA successfully integrates into the host genome as a provirus.
In all cases, INT is responsible for catalyzing two important reactions: 3’-end processing
and strand transfer events. The former reaction involves the removal of two nucleotides on
the 3’ ends of the dsDNA viral genome to generate reactive 3’ hydroxyl ends that are
biochemically primed for integration into the host genome. During strand transfer,
integrase uses the 3’-hydroxyl groups to nucleophilically attack a 5’-α-phosphate in the
major groove of host DNA, while the D,D(35)E motif within integrase, comprised of three
evolutionarily conserved amino acid residues (Asp64, Asp116, and Glu152), chelates two
Mg+2 ions to mitigate unfavorable charge interactions between host DNA and viral DNA
during nucleophilic attack81. Following this, single-stranded gaps created during
integration are repaired using host DNA repair machinery.
Integration, is not a random process. It favors transcriptionally active genes82,83. Integration
site analyses within infected individuals have shown HIV integration into highly
transcribed genes, especially those encoding transcriptional regulator protein (BACH2),
myocardin-like protein 2 (MLK2), and signal transducer and activator of transcription 5B
(STAT5B)84,85. Interestingly, all three genes correspond to cellular growth factors, whereas
BACH2 and MLK2 are reported to have proto-oncogenic functions. High levels of viral
integration have also been shown to correlate with genes that have specific histone marks.
Specifically, acetylation of histone H3 lysine at position 9 (H3K9ac) and trimethylation of
histone H3 lysine at position 36 (H3K36me3), have been shown to be associated with
highly transcribed genes, and are often correlated with sites of viral integration, supporting
the notion that HIV preferentially integrates into highly transcribed regions of the genome.
Host lens epithelium-derived growth factor (LEDGF) binds to integrase through its Cterminal integrase-binding domain (IBD), while the N-terminal Pro-Trp-Trp-Pro (PWWP)
domain binds H3K36me3, effectively tethering integrase to euchromatin. In fact, depletion
of LEDGF results in a drastic shift of integration away from actively transcribed genes86–
89

. Although both CPSF6 and LEDGF play significant roles in targeting the viral genome

into euchromatin, tandem knockout studies reveal that CPSF6 is more dominant in
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euchromatin targeting activity; however, a reduction in either CPSF6 or LEDGF
expression can shift integration into heterochromatic regions of the genome89. Therefore,
a two-phase mechanism that involves both LEDGF and CPSF6 is most probable. It is
suggested that CPSF6 binding to capsid protein docked to the nuclear pore complex is a
prerequisite for directing integrase-LEDGF to euchromatin. Spatially, integration
preferentially occurs in genes located near the periphery of the nucleus, underlying the
nuclear pore complex90. Genes located within the center of the genome that are highly
repressed through heterochromatinization are highly disfavored for integration. To this
effect, in situ hybridization by 3D immunofluorescence corroborates this phenomenon as
HIV integration sites are consistently found within euchromatin structures that are 1 µm
away from the nuclear periphery and the nuclear pore complex91. Taken together, regions
of euchromatin found under nuclear pore complexes near the nuclear periphery will be the
preferred sites of integration and viral expression. Transcription of the provirus results in
transcripts that are either exported as unspliced RNA for packaging into virions, or
extensively spliced and exported from the nucleus to produce viral transcripts and generate
viral particles92. A schematic overview of the HIV replication cycle is described in Figure
4.
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Figure 4. Schematic Overview of HIV Replication Cycle

Viral fusion is triggered by gp120 interaction with CD4 and co-receptor CCR5/CXCR4.
Upon entry, viral uncoating and reverse transcription occur before the viral genome is
imported into the nucleus and integrated into host chromosome. Proviral transcripts are
exported from the nucleus and are used for translating HIV proteins. These proteins selfassembled

1.2.3 Immunology of HIV Infection
Once the virus disseminates from the mucosa to local draining lymph nodes, an
evolutionary arms race between the host immune system and the TF virus ensues. Due to
a combination of factors stemming from the lack of RT proofreading mechanisms, high
frequency of viral recombination, and host APOBEC3-mediated substitutions of the viral
genome, viral diversity greatly expands. Additionally, during acute stages of infection,
cytotoxic T lymphocyte (CTL) responses place a positive selection pressure on the virus,
fueling the evolution of CTL escape mutants. Most escape mutations occur within viral
epitopes that are recognized by T cells. Viral escape is further maintained, through the
concerted actions of HIV Nef-mediated downregulation of HLA-A, B, and C on infected
CD4+ T cells93. Because the virus preferentially infects activated T cells, the persistent viral
replication ongoing within lymph nodes only accelerate the apoptotic death of responding
CD4+ T cells while pyroptosis decimates T cells expressing TCRs of non-HIV specificities
94

. As a result, systemic T cell counts gradually decline. The virus eventually disseminates

into the gut-associated lymphoid tissue (GALT)–an anatomical site rich in T and B
lymphocytes. Permissive CD4+ T cells fuel the rapid explosion of virus propagation within
the lamina propria of the GALT. CD4+ T cell counts subsequently plummet as a result of
cell death associated with viral cytopathic effects (vCPE) and pyroptosis of uninfected
bystander cells94. In the absence of prompt medical intervention, individuals experience
acute HIV syndrome within 3-6 weeks, characterized by high plasma viremia as the
immune system deploys humoral and cellular-mediated responses to counteract the
infection95. However, the immune response is unable to resolve the infection, and HIV
continues replicating in CD4 T cells and within primary and secondary lymphoid tissues.
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Following peak viremia, the contraction phase of infection begins and is marked by the rise
of CD8 CTLs and viral escape mutants. The viral loads continue to decline until a viral set
point is reached, which is then maintained until such time as the immune system is
completely degraded and the infected individual progresses towards AIDS. Over the course
of infection, excessive antigen exposure and continual stimulation of CD8+ and CD4+ T
cells promotes functional exhaustion of both populations of T cells. Evidence suggests
these exhausted T cells express high levels of inhibitory receptors, such as PD-1, Tim-3,
and CTLA-4, resulting in severely compromised adaptive anti-viral responses96–98. In
addition to weakening a critical cellular component of the immune response through the
combined efforts of CTL escape, CD4+ T lymphocytopenia and T cell exhaustion, HIV
induces the immunological dysfunction of other immune cells99. For example,
hypergammaglobulinemia induced by clonal B cell expansion, Ig class switching, and
differentiation are readily found within HIV-infected individuals100,101. Lymph nodes
contain B cell follicles, where IgM+ IgD+ B cells reside and are superficially separated from
the subcapsular sinus by the interfollicular zone. During adaptive immune responses, the
B cell follicle cultivates the formation of a germinal center, at the center of which lies a
network of follicular dendritic cells (FDC) responsible for promoting B cell survival.
Underlying these structures and bordering each B cell follicle is the T cell zone, which as
the name suggests, consists of T cells but also contains DCs. There is evidence suggesting
that these FDCs can present virus to naïve B cells through long-lived complement receptormediated structures called iccosomes102,103. The resulting B cell receptor cross-linking,
antigen internalization, and presentation on MHC II allows the B cell to migrate to the
border of the B cell and T cell zones. Here, follicular T helper (TFH) cells provide the
necessary

cognate

interactions

and

co-stimulatory

signals

to

induce

hypergammaglobulinemia through B cell clonal expansion, Ig class switching, and
differentiation. The sustained deterioration of the immune system often clinically manifests
as an acquired immunodeficiency syndrome (AIDS)-defining illness. Individuals at this
stage of infection are severely immunocompromised and have poor prognoses due to their
inundation with opportunistic infections and/or cancer104.

16

1.3 Antiretroviral Therapy
In the early 1990s, inhibitors for reverse transcriptase, such as Zidovudine and Didanosine
were used extensively as monotherapies. Interestingly, Zidovudine was the first
antiretroviral therapy approved for use against HIV. These nucleoside analog reversetranscriptase inhibitors (NRTI) compete with cellular deoxynucleotides for incorporation
into the growing strand of DNA produced by reverse transcriptase. However, the NRTI
does not contain a 3’-hydroxyl group that can be further elongated, resulting in a premature
chain termination event. Due to the high viral turnover rates and large viral population size
during acute stages of infection, the propensity of resistant mutants appearing after single
therapy is much higher compared to the use of combination therapies. Therefore, during
the mid-1990s, the standard of care evolved to include dual therapy treatment regimens,
which usually included a reverse transcriptase inhibitor and a protease inhibitor. The latter
of which suppresses the production of infectious virions by inhibiting proteolysis of viral
polyproteins. Interestingly, mathematical modelling suggested a minimum of three
mutually independent mutations must be established to subvert a durable inhibition of HIV
replication under combination therapy105. Therefore, in the late 1990s, combined antiretroviral therapy (cART) was introduced by leveraging three or more different
antiretroviral drugs, targeting several targets of viral replication, to effectively mitigate the
chances of accruing viral resistance. These additional classes of antiretroviral drugs
included non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase inhibitors,
fusion inhibitors, and co-receptor antagonists.
To date, cART is the only effective treatment for individuals infected with HIV, and
effectively prevents progression to AIDS106. Many infected people are unaware of their
HIV status107. Of those that are aware, a significant proportion often have immense
difficulty in accessing cART due to various social and economic constraints108. Despite the
countless lives that have been saved by this therapy, without a curative approach to
eradicate the disease, HIV infection remains a significant healthcare burden due to its
manifestation as a life-long treatment-manageable, chronic infection. If cART is
interrupted, rapid viral rebound occurs within days. This is suggestive of a discrete
population of latently infected cells harboring replication-competent provirus that is
rapidly reactivated when the suppressive actions of cART are removed. It therefore follows
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that cART is unable to facilitate a sterilizing cure due to replication-competent HIV that
persists despite antiretroviral therapy.

1.4 The Latent Reservoir
1.4.1 How the Latent Reservoir is Established
Studies characterizing the latent reservoir have provided evidence suggesting that latency
is “hardwired” into the HIV genome through a gene-regulatory circuit that maximizes
transmission by minimizing viral extinction109,110. The most well-characterized repository
for these replication-competent proviruses are within a mono- or oligoclonal population of
resting memory CD4+ T cells, termed the latent reservoir. Other characterization studies in
resting CD4+ T cells that comprise majority of the latent reservoir have shown that dNTP
levels are 10- to 100-fold lower than their activated counterparts, which in concert with
other mechanisms, effectively “traps” the HIV provirus and contributes to the maintenance
of the latent reservoir111–113.
During infection of activated T cells, the viral infection is often productive and results in
Caspase-3 activation and rapid apoptotic cell death114. However, within a very small
proportion of activated T cells, viral integration as a provirus can occur concomitantly with
the transition of the T cell into a memory phenotype. As cells transition into resting memory
T cells, the cell cycle enters G0, characterized by a low metabolic state. The transition into
G0 is marked by repression of transcriptional machinery to facilitate cellular quiescence.
Cellular levels of NF-κB, AP-1, NFAT are significantly downregulated upon entry into G0,
and therefore cannot facilitate transcription from the 5’ LTR. Moreover, in quiescent cells,
the cyclin T1 (CycT1) subunit of the positive transcription elongation factor b (P-TEFb) is
rapidly degraded. This silences all transcriptional initiation as P-TEFb is sequestered and
inactivated within 7SK small nuclear ribonucleoprotein (snRNP) complexes that contain
hexamethylene bis-acetamide-inducible (HEXIM) 1/2 repressor proteins. Furthermore,
several epigenetic mechanisms ensure proviral latency is maintained. Regardless of the
location of proviral integration, two nucleosomes (Nuc-0 and Nuc-1) position themselves
on the 5’ LTR. Modification of histones within Nuc-0 and Nuc-1 through histone
deacetylases (HDAC) and histone methyltransferases (HMT) result in heterochromatic
silencing. The resulting heterochromatic structure also induces RNA polymerase II
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promotor-proximal pausing, resulting in inefficient proviral transcription during latency115.
In fact, in latently infected cells, up to 3% of chromatin-associated RNA polymerase II can
be found paused proximal to promotors within the 5’ LTR. In addition to promotorproximal pausing, proviral transcription is impeded by its abortive nature during latency
because of low Tat availability. This is because low Tat in latently infected cells induces
premature termination of any elongating RNA polymerase II. This is achieved by the
recruitment of the negative elongation factor (NELF) through DRB sensitivity-inducing
factor (DSIF), which recognizes nascent RNA emerging from RNA polymerase II116. It
therefore becomes apparent that the state of viral latency is sensitive to the availability of
Tat. In fact, there are two transcriptional circuits that are activated based on Tat
availability117. When high levels of viral Tat are available, a complete transcriptional
circuit is established wherein Tat production outcompetes NF-κB binding to CDK9,
enabling hyperphosphorylation of the C-terminal domain of RNA polymerase III, which
further increases transcriptional activation of the provirus. In contrast, when low levels of
viral Tat are available, an incomplete transcriptional circuit is established because Tat
levels are too low to outcompete NF-κB binding to CDK9. As a result, only a basal level
of transcriptional activation is initiated118,119. Taken together, these are some of the
mechanisms that promote the transcriptional pausing of proviral genes, effectively trapping
the HIV provirus within the cell and seeding the latent reservoir120.
Despite these restrictions, replication-competent proviruses within the latent reservoir
retain the capacity to reignite viral replication upon T cell receptor stimulation and/or
cytokine-mediated activation121–123. Following T cell receptor stimulation of latently
infected cells, a signaling cascade is initiated, mobilizing NFAT and NF-κB into the
nucleus. These proteins subsequently recruit histone acetyltransferase (HAT) complexes
such as CBP/p300, that remove heterochromatic silencing induced by HDACs or HMTs
and allow for euchromatic proviral expression. As transcripts are being produced, Tat
levels within the cell correspondingly increases through a positive-feedback loop,
characteristic of a complete transcriptional circuit. This is because Tat binds strongly to
P-TEFb, which is displaced from the repressive 7SK snRNP complex upon Tat binding.
The Tat-P-TEFb complex subsequently recruits the super-elongation complex (SEC),
which activates productive RNA polymerase II elongation complexes. This conversion of
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RNA polymerase II from a promotor-proximal paused state into a processive state
requires promotor clearance. This is mediated by phosphorylation of the C-terminal
domain of RNA polymerase II, which is catalyzed by CDK9 and the kinase activity of the
Tat-P-TEFb complex.
Evidence supporting the existence of the latent reservoir can be gleaned from studies
characterizing viral kinetics during cART administration. The primary drastic reduction of
plasma viremia upon cART initiation often underscores a secondary slower decay of
viremia. The slower decay kinetics reflect a slow cell turnover rate that deviates
significantly from the short turnover of productively infected cells. Upon further
characterization, the slow decay kinetics were found to be associated with latently infected
memory CD45RO+, HLA-DR– CD4+ T cells124. The intrinsically long-lived property of
this cell population, combined with stem cell-like regenerative capabilities imbued by
homeostatic proliferation, results in a persistent latent reservoir harboring provirus. There
are seven main families of resting memory CD4 T cells, each of which show differential
permissivity towards latent HIV infection. In particular, the long-lived central memory T
cells (TCM) are most permissive and contain the highest proportion of cells that are latently
infected, whereas shorter-lived populations such as transitional memory (TTM) and
effector memory (TEM) T cell populations contain less125. Although the cellular
composition of the latent reservoir remains relatively similar between chronically infected
and acutely infected individuals, the size of the latent reservoir in acutely infected
individuals is significantly smaller than those found in chronically infected individuals.
This phenomenon is heavily influenced on the timing of cART, with early antiretroviral
intervention significantly limiting the amount of cells harboring HIV DNA125,126.
Several longitudinal evolutionary studies of HIV Env diversity following cART
interruption have provided evidence that the latent reservoir is seeded during very early
stages of infection. In one such study, 46 chronically infected patients were subjected to
multiple two-week structured treatment interruptions. Env was sequenced from the
resulting swarm of rebound virus, and was found to be highly homogenous, which is
consistent with a virus of monoclonal or oligoclonal origin and is genetically reminiscent
of early TF strains127. Importantly, evidence from SIV infection in rhesus monkeys have
elucidated details that uncover the influence of time until cART initiation, on the
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characteristics of the latent reservoir. In one such study, rhesus monkeys were distributed
among four experimental groups corresponding to increasing time of cART intervention
following intrarectal SIV challenge (3 days, 7 days, 10 days, 14 days). There was an
apparent inverse correlation between the time taken to administer cART following
exposure, and the time it takes to experience viral rebound. In fact, monkeys that were
administered cART 3 days post-SIV challenge displayed threefold delayed kinetics
compared to monkeys administered cART 14 days post-challenge52. These findings
corroborate details found within the interesting “Mississippi Baby” case who acquired the
infection in utero. In 2010, a baby girl–popularized as “The Mississippi Baby”–was born
to a mother who was found to be HIV+ only during labor due to lack of prenatal care. As a
result, the normal standard of care of administering cART prior to childbirth could not be
achieved, which would have in retrospect, prevented vertical transmission of HIV to the
baby. As expected, soon after birth, the Mississippi Child was determined to be HIV+ and
was treated with an aggressive course of cART within 30 hours of her birth. The
Mississippi baby tested positive for HIV at 6, 11, and 19 days old; however, when the
Mississippi Baby was 29 days old, HIV RNA copies decreased below detectable levels (<
20 copies per mL). When she was 18 months old, the mother reported that she had stopped
administering cART to the baby. Remarkably, after a year of cART cessation, viral RNA
copies were still undetectable in blood. However, when the girl became 4 years old, she
experienced a significant viral rebound, which resulted in viremia present at 10,000
copies/mL. Until the initiation of the viral rebound, she had been – for all intents and
purposes –functionally cured, since her viral titers had remained below detectable levels.
The case of The Mississippi child illustrates that despite early cART intervention, the latent
reservoir is seeded extremely rapidly. In support of this idea, cART initiation during later
stages of infection results in a higher proportion of resting memory CD4+ T cells harboring
provirus containing CTL escape mutations. This is reflective of the predominance of CTL
escape mutants during later stages of infection. In contrast, when cART is administered
during very early stages of infection, CTL responses are not fully developed, and adaptive
immune responses have not been mobilized. Correspondingly, the latent reservoir from
these individuals is limited in size and proviruses do not contain CTL escape mutations128.
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In the absence of cART intervention, a single latently infected T cell that is stochastically
activated has the potential of producing viral particles that can infect other T cells. This
rebounding virus can result in an explosion of virus production. In fact, there is substantial
evidence in humans and in non-human primate models of infection, describing that viremia
can be detected within days to weeks of cART cessation129. In fact, the latent reservoir is
thought to be very stable and if solely relying on cART and stochastically reactivating
virus, the latent reservoir would require >70 years of continuous cART in order for it to
decay to the extent that a cure could be realized. Therefore, continual, unabated cART, is
unlikely to constitute a cure on its own. This highlights the importance of developing
additional curative interventions against HIV through the eradication of the latent reservoir.

1.4.2 Approaches for Eradicating the Latent Reservoir
Studies investigating the control of HIV latency have been seminal in understanding
mechanistic approaches to eradicate the latent reservoir. However, the accuracy of these
studies is greatly hindered by the low frequency of latently infected cells in vivo. Therefore,
the use of various cell lines to model and quantify latency have been highly advantageous.
However, these in vitro models cannot fully recapitulate the physiological conditions of a
quiescent G0 cell state. Apart from the Verdin model of latency, which uses Jurkat-derived
T cell clones, all models utilize primary CD4+ T cells that are spinoculated with either
GFP-based or luciferase-based HIV reporter constructs. However, only results obtained by
the quantitative viral outgrowth assay (QVOA) offer the most accurate representation of
latency. This is because QVOA estimations of reservoir size measure frequency of
endogenous provirus within primary cells, whereas other estimations use cell lines. Since
cART is unable to eradicate the latent reservoir within a reasonable timeframe, alternative
approaches to purposefully activate latently infected cells are being investigated. The HIV
cure field has rallied around the “shock and kill” approach to eradicating the latent
reservoir130,131. This approach uses T cell activating agents, termed latency reversal agents
(LRA), designed to reactivate latently infected T cells. In doing so, the cell cycle exits G0,
and the pool of transcription factors increases. Subsequent virus transcription can be
initiated by transcription factor binding of proviral 5’ LTR and induce virion production.
This process of forcing the virus out of hiding, constitutes the “shock” aspect of the
approach. As soon as latently infected cells begin to produce virus, they are exposed to a
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combination of immune-mediated and/or viral cytopathic-mediated destruction,
constituting the “kill” aspect of the approach. The foundation of this strategy is the
simultaneous delivery of LRA and cART, which respectively function to accelerate the
decay of the latent reservoir and inhibit de novo infection of healthy CD4+ T cells. Early
LRAs attempted to induce latency reversal via global T cell activation. Here, combinations
of IL-2 and anti-CD3 antibodies were screened for latency reversal potential

132,133

. An

alternative strategy was also explored, which involved protein kinase C (PKC) agonism
using synthetic or naturally occurring ingenol compounds. These compounds are molecular
mimics of diacylglycerol (DAG), which activate PKC. Activated PKC is capable of
sequestering inhibitory IκB and would free NF-κB to bind the proviral 5’ LTR and activate
transcription134,135. One of the more promising pharmacological LRAs have been the class
of histone deacetylase inhibitors (HDACi), which include compounds such as vorinostat,
panabinostat, and romidepsin. A component of proviral latency relies on the epigenetic
repression of transcription through localized heterochromatization, mediated by histone
acetylation. Therefore, inhibition of enzymes responsible for catalyzing the acetylation
reaction may induce euchromatinization, which would in turn promote proviral
transcription. Another class of LRAs are the bromodomain and extra-terminal domain
inhibitors (BETi), such as JQ1. These molecules activate P-TEFb signaling by inhibiting
bromodomain-containing protein 4 (BRD4). Since BRD4 competes with Tat for binding
P-TEFb, inhibiting BRD4 increases the proportion of P-TEFb bound by Tat, which can
subsequently initiate proviral transcription.
The latency reversal capabilities of toll-like receptor (TLR) agonists have also recently
been explored. In addition to other pattern recognition receptors (PRR), TLRs are sentinel
receptors of the innate immune system that detect pathogen-associated molecular patterns
(PAMP) and activates immune signaling cascades to mount an appropriate counterresponse. Several studies have shown that this counter-response is strong enough to
reactivate resting CD4+ T cells. For example, a TLR1/2 agonist PAM3CSK4 has been
shown to induce viral reactivation from a cultured population of central memory T cells
isolated from five aviremic individuals136. Flagellin, a TLR5 agonist, has been shown to
induce latency reversal in J-lat and Jurkat latently infected cell lines, and central memory
T cells isolated from two aviremic individuals137. TLR3 activation using poly(I:C) has been
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shown to induce latency reversal in the HC69 cell line, which are immortalized microglial
cells138. MGN1703 is a synthetic TLR9 agonist currently in phase 3 clinical trials for the
treatment of metastatic colorectal cancer. This compound was shown to enhance both
proviral transcription and NK-mediated killing of latently infected cells139. TLR7/8
agonists like GS-9620 and imiquimod have shown to reduce the size of the latent reservoir
in SIV-infected rhesus macaques, and enabled two of nine animals to remain aviremic for
two years after cART cessation140. These TLR7/8 agonists induce the production of T1
IFNs and other antimicrobial countermeasures (Fig 5). Although the these LRAs are
capable of inducing detectable latency reversal, they fail to consistently reduce the overall
size of the latent reservoir, measured by QVOA models of latency reversal141–143.
Importantly, due to the promiscuity of these LRAs, these strategies may correlate with
significant side-effects associated with massive cytokine release144 induced by widespread
T cell activation. Unlike TLR7/8 agonists, other non-specific LRA are unable to stimulate
IFN responses, which precludes clearance of the latent reservoir mediated by anti-viral
effects145. In particular, the use of HDACi as an LRA is a double-edged sword, as this class
of molecules has been associated with inhibition of cytotoxic T cell responses, which
would ultimately undermine the “kill” arm of the “shock and kill” strategy146. It therefore
follows that latency reversal should be a more targeted approach.
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Figure 5. Detection of Virally Packaged RNA through Endosomal TLR7/8
Virally packaged RNA induces dimerization of TLR7 or TLR8, which allows recruitment
of MyD88 to the Toll/IL-1R (TIR) domain of TLR7/8. This enables an adaptor protein
MyD88 to bind and activate IRAK4/TRAF6, which activates a complex of
TRAF3/IRAK1/IKKα resulting in the phosphorylation of IRF7 and its translocation into
nucleus. Here, IRF7 enables the transcription of type I IFN genes. In addition, the
MyD88/IRAK4/TRAF6 complex ubiquitinates NEMO and TAB proteins resulting in the
activation of TAK1. Subsequently, activated TAK1 phosphorylates IκB kinase (IKK)
complex, enabling the phosphorylation of the inhibitory IκB subunit of NF-κB. This
enables NF-κB translocation into the nucleus where it stimulates genes responsible for
enacting antimicrobial countermeasures such as defensins, iNOS, and TNFα.

1.4.3 Targeted Reactivation of the Latent Reservoir
Targeting the latent reservoir requires identifying cells that harbor provirus; however, this
task has been a major stumbling block for cure research. Recent advances have suggested
several markers may be characteristic of latently infected cells. This includes CD32a,
whose expression has been reported to be high within T cells that are latently infected,
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whereas bystander cells showed little to no detectable expression147. This phenomenon
suggests some mechanism of latency may be involved in the upregulation of CD32a.
However, conflicting evidence showing no enrichment of HIV-1 DNA from CD32a+ CD4
T cells suggest that this phenomenon may be an artifact of adherent non-T cells bearing
this marker148.
However, there are three lines of evidence suggesting that the latent reservoir is mostly
comprised of memory T cells with T cell receptor (TCR) specificities towards HIV
antigens. In a study by Demoustier et al., the antigen specificity of purified CD4+ T cells
from five aviremic HIV infected individuals on cART were characterized by activating
cells with either HIV-derived antigens or other common antigens (e.g. tuberculin purified
protein derivative, peptides from cytomegalovirus)149. Based on the proportion of activated
T cells in response to HIV-derived proteins, relative to T cells activated in response to
common antigens, the pool of HIV-specific T cells was estimated to be 5- to 100-fold
greater than T cells with alternative antigenic specificities149. Secondly, in a study by
Douek et al., more proviral HIV DNA was found within memory CD4+ T cells that were
HIV-specific compared to CMV-specific memory CD4+ T cells150. Thirdly, HIV latency
reversal has been shown to be induced using HIV-derived peptides151–153. Hence, our group
previously hypothesized that the direct TCR stimulation of latently infected T cells using
HIV-derived antigens, that covers a diverse repertoire of HIV-specific TCR epitopes, may
maximally trigger the latent reservoir into transcriptional activity i.e. shock the virus. Since
we, and others, hypothesize that a significant proportion of the latent reservoir consists of
CD4+ T cells expressing HIV-specific TCRs, our group’s initial effort was focused on
targeting HIV-specific T cells for reactivation. To do this we first engineered an HIVderived virus-like particles (VLP) vaccine formulation, based on the quasi-species found
in HIV subtype B infected individuals who were diagnosed and treated at the chronic stage
of infection. The use of VLPs as both an antigen delivery and latency reversal platform
were highly attractive for our research for several reasons. These non-infectious ordered
arrays of genomeless, self-assembling viral proteins, mimic native virion structure154 are
antigenic, noninfectious and easy to produce. Furthermore, VLPs – despite being a
relatively new technology – have garnered great success at translating to clinical
application. For instance, the high protection efficacy of Gardasil®–a Human

26

Papillomavirus (HPV) VLP– and RECOMBIVAX®– a Hepatitis B VLP formulation are
both commonly administered today and offer some of the highest levels of protection of
any vaccine, in this case against Hepatitis B and different strains of HPV

155

. Another

attractive property of VLP vaccines is their particulate structure, allowing them to be
efficiently internalized and processed by antigen-presenting cells (APC), which we
believed to be advantageous in terms of APC presentation to CD4 T cells. Finally, VLPbased vaccines are capable of inducing strong humoral responses due to their polyvalent
nature, and ability to efficiently crosslink B-cell receptors and activate B cells.
Our initial studies using the VLPs to trigger proviral transcriptional activity demonstrated
that the VLPs were efficient latency reversal agents. In fact, the VLPs were able to induce
more HIV latency reversal than all clinically relevant LRAs tested, including HDACi and
PKC agonists (manuscript submitted). To demonstrate specificity of the targeting, we
compared latency reversal induced by VLPs against other antigens such as common recall
antigens (i.e. Flu M1 peptide pool, tetanus toxoid protein, CMV peptide pools, Ebola
(EBV) gp42 protein) and against other viral particle formulations such as feline
immunodeficiency virus (FIV) VLPs and simian immunodeficiency virus (SIV) VLPs.
Latency reversal was determined using an ex vivo DC-T cell co-culture assay and optimized
qRT-PCR assay. The results consistently showed that HIV antigens cause greater latency
reversal compared to other immunostimulatory antigens.
The advantage of HIV VLPs over other immunostimulatory formulations lies in its
capacity to deliver a diverse array of HIV proteins and therefore activate a diverse range
of CD4 T cells specific against HIV peptides. The diversity contained in the VLP-based
LRA vaccine, should in theory, enable the vaccine to have a more global application,
although this would need to be tested in blood samples derived from individuals presenting
with differing subtypes of HIV infection. Previous studies exploring HIV cure used
dendritic cell-based vaccines designed to elicit antiviral T cell responses for invoking antiviral CTL responses. These studies involved DC-mediated presentation of autologous virus
or viral peptides for targeted reactivation of the latent reservoir in both humans and in the
rhesus macaque-SIV model. To this extent, a study that vaccinated macaques with
chemically inactivated SIV-pulsed DCs showed an effective and durable SIV-specific
humoral and cellular immunity. Over the course of the study (34 weeks) these animals
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sustained a 50-fold decrease of SIV DNA and a 1000-fold decrease in SIV RNA found in
peripheral blood156. In a similar study, a therapeutic DC-based treatment with autologous
aldrithiol-inactivated HIV-1 resulted in a 80% decrease in median viral loads over 112 days
following immunization157. These studies attributed the DC-mediated presentation of HIV
antigens to effectuating a CTL-mediated control. However, to our knowledge, our group is
the first to provide evidence suggesting that the decline in latent reservoir size using DC
presentation of HIV antigens, may not be associated with CTL control. Rather, it may be
due to a “shock” effect which induces transcriptional reactivation of the provirus
(manuscript under review).

1.5 Hypothesis, Rationale, and Objectives
Initial characterization studies with HIV VLPs revealed that they were less antigenic than
a related viral particle (VP) formulation containing packaged HIV RNA. Interestingly, the
only difference between the VP and VLP formulations is: the presence or absence of
packaged HIV RNA. This observation raised several lines of questioning (Fig 5): whether
virally packaged RNA in VPs increases virion antigenicity by its intracellular recognition
by PRRs; whether changes in antigenicity are correlated to changes in latency reversal
potency; and if the prior two hypotheses are true, whether a heterochthonous packagingcompetent RNA containing immunostimulatory motifs could replace HIV RNA and
augment VLP antigenicity and latency reversal. To address these questions, we established
three main objectives:
1. Determine whether TLR stimulation can enhance HIV VLP-mediated latency
reversal.
2. Characterize the relative antigenic contribution of packaged HIV RNA in VPs,
and the impact this has on latency reversal.
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3. Design and generate an immunostimulatory RNA that can be packaged into HIV
VLPs.

Figure 6. Overarching hypotheses of this thesis
Here we assess whether packaged RNA within VPs can augment antigenicity and latency
reversal capacity through interactions with cellular pattern recognition receptors when HIV
VPs are endocytosed by antigen-presenting cells like DCs.

2

Chapter 2 – Materials and Methods
2.1 Generation of HIV-derived VLP and VP
VLPs and VPs were generated as described previously in detail

158

. Briefly, serum from

HIV+ volunteers infected with subtype B virus were collected, and viral RNA was extracted
using viral RNA isolation kit (Qiagen, USA) according to manufacturer instructions. Viral
genomic RNA was subsequently reverse transcribed using Superscript III reverse
transcription kit and random hexamer primers (Thermofisher, CA) adhering to
manufacturer instructions. This yielded two overlapping 5’ and 3’ cDNA fragments that
were cloned into an in-house yeast recombination vector, pREC ΔGag/URA3 using a
yeast-based recombination system described previously
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. Both VP and VLP-encoding

vectors contained a deleted 5’ LTR and non-functional integrase. However, the VLPencoding vector contained extensive mutations in the HIV packaging structure (Ψ), unlike
the VP-encoding vector, which contained an intact Ψ.
Following recombination, successful transformants were positively selected on complete
yeast media plates lacking uracil and containing 5-fluoroorotic acid (5-FOA).
Untransformed yeast cells contain a URA3 gene that converts 5-FOA into toxic 5’
fluorouridine monophosphate, thereby severely impairing cell growth. Recombinant
plasmid DNA was extracted from yeast using a standard phenol-chloroform isolation
before transforming into DH5α bacteria and purifying the recombinant plasmid using a
plasmid DNA maxiprep kit (Qiagen).
HEK 293T cells were cultured at 37˚C and 5% CO2 in T-175 flasks until cells reached 70%
confluency. Cells were then transfected with 20 µg of VLP/VP-encoding plasmid per flask
using 80µL of polyethylenimine (1mg/mL) and cultured for an additional 72 hours. To
generate adjuvanted VLPs, cells were transfected with 10 µg of VLP-encoding plasmid
and 10 µg of plasmid encoding the immunostimulatory RNA. Particles were purified
through 100 kDa MWCO centrifuge tubes (Millipore, CA) before pelleting particles using
ultracentrifugation at 100,000 G (Beckmann, USA). Virus pellet was resuspended in PBS,
aliquoted, and subsequently stored at -80˚C until required.
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2.2 p24 Enzyme-Linked Immunosorbent Assay (ELISA)
A high binding 96-well plate (Sigma-Aldrich, CA) was coated with pp267 (NCI,
Frederick), which is a polyclonal anti-p24 antibody. After diluting at 1:1000 in PBS, each
well was coating with 100 µL of pp267 solution at 37 ˚C for 2 hours, or 4 ˚C overnight.
The plate was subsequently washed three times in PBS with 0.05% Tween-20 (Sigma,
CA). Then, 200 µL of blocking solution (PBS + 10% fetal bovine serum) was added to
each well before incubating for 30 minutes at room temperature. The blocking solution
was then discarded before washing the plate three times as previously rdescribed.
Following this, 100 µL of transfection supernatant serial dilutions were loaded in
duplicates in addition to a p24 standard (NCI, Frederick), the latter of which was run in
duplicate starting at 10,000 pg/mL down to 156.25 pg/mL. All wells then received 11µL
of 0.031M Triton X-100 (Thermo Fisher, CA). After incubation at 37 ˚C for 2 hours, 100
µL of the primary antibody solution (complete DMEM supplemented with 0.1% rabbit
anti-p24 antibody and 2% normal mouse serum) was added and incubated at 37 ˚C for 1
hour. Subsequently, 100 µL of the secondary antibody solution (complete DMEM
supplemented with 0.05% goat anti-rabbit IgG conjugated to HRP, 2% normal mouse
serum, and 5% normal goat serum) was added to each well and incubated at 37 ˚C for 1
hour. The reaction was developed by adding 100 µL of TMB (Seracare, Milford, MA) for
15 minutes before inactivating the reaction by adding 100 µL of 0.5M H2SO4. The plate
was subsequently read at 450 nm on a Cytation 5 Imaging Reader (BioTek).

2.3 PBMC Isolation from Whole Blood
PBMCs were isolated from whole blood using density centrifugation in SepMate™ columns
according to manufacturer’s protocol. Briefly, 15 mL of Ficoll-Paque™ was pipetted into
the central hole of the SepMate™ insert. Following this, whole blood from donors were
diluted in an equal volume of PBS + 2% FBS and carefully added to the column to prevent
any sample from entering the central hole. Columns were then centrifuged at 1200 G for
10 minutes at room temperature. Subsequently, the top layer containing the enriched
population of mononuclear cells was carefully poured into a new tube. PBMCs were then
washed twice with 20 mL of PBS + 2% FBS before centrifugation at 300 G for 8 minutes
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before resuspending the PBMCs in an appropriate volume of 90% FBS and 10% PBS and
aliquoted into cryotubes for storage such that each vial contained 1 × 10$ cells.

2.4 Dynamic Light Scattering
Before loading the appropriate sample onto the DynaPro dynamic light scattering
apparatus (Wyatt Technology, CA), it was diluted 100-fold in 1X PBS, and 10 µL of
sample was loaded into a glass cuvette at 25 °C. Twenty independent read events were
collected for each sample for analysis.

2.5 Latency Reversal Assays
PBMCs were isolated from HIV+ donor whole blood as previously described. The
volunteers used in these studies were diagnosed and cART treated at acute stage of HIV
infection and were able to suppress viremia to <50 copies HIV-1 RNA/mL. Additional
inclusion criteria include that the volunteers were on cART for >6 months and had no
detectable viral blips. On day 0, PBMCs were seeded into T-175 flask (ThermoFisher, CA)
with RPMI-1640 growth media (Wisent, CA) supplemented with 300 mg/L of LGlutamine, 10 U/mL Penicillin, 10 U/mL Streptomycin, and 10% heat-inactivated fetal
bovine serum (Wisent, CA). To generate monocyte-derived dendritic cells (MDDCs),
PBMCs were plastic-adhered for 2 h, after which the media was supplemented with 500
U/mL IL-4 and 1000 U/mL GM-CSF. After culturing cells for 6 days, the MDDCs were
pulsed with VLPs by co-culturing DCs with VLP (5 µg/mL based on p24). On the same
day, 1 × 10% autologous T cells were purified from PBMCs using a magnetic-bead
negative selection kit (Milltenyi Biotech, CA) Briefly, non-CD4+ T cells were labelled
with biotin-conjugated antibodies, which were then magnetically labelled. CD4+ T cells
were then isolated through the depletion of magnetically labelled cells. and were used the
following day. Pulsed MDDCs and autologous T cells were co-cultured for 6 days with
media being replaced every 3 days. Latency reversal was measured by IFN-γ ELISpot, as
a proxy for T cell activation, and copies of HIV RNA in culture supernatant corresponding
to recrudescent virus was measured by qRT-PCR using 5’LTRPA primers binding to the
5’ HIV LTR.
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2.6 Yeast-based DNA Recombination
Saccharomyces cerevisiae was scraped from a YPD starter culture plate and grown
overnight in YPD media at 37 °C on a shaking incubator at 225 RPM. The following day,
the culture was centrifuged at 2377 g for 5 minutes. The supernatant was discarded, and
the yeast pellet was washed with 1 mL of deionized water. This was subsequently
centrifuged at 1946 G for 5 minutes. The supernatant was subsequently removed, and the
pellet was resuspended in 500 μL of 0.155 M lithium acetate (pH 7.5) and 0.15M TrisEDTA (TE) buffer (pH 8.0) and incubated for 2 hours at 30 °C. Subsequently, the
recombination mixture was assembled by mixing 100 μL of the yeast mixture with 600 µL
polyethylene glycol (PEG) mixture (600 µL 10X lithium acetate solution, 600 µL 10X
Tris-EDTA buffer, and 4.8 mL of 50% w/v PEG BioExtra 3350) (Sigma-Aldrich, CA).
The recombination mixture was incubated at 30 °C for an hour before incubating for an
additional 15 minutes at 42 °C. Yeast were then centrifuged at 1946 G for 5 minutes and
resuspended in 200 μL of water before plating on CSM–Leu+5-fluoro-1,2,3,6-tetrahydro2,6-dioxo-4-pyrimidine carboxylic acid (FOA)-containing plates. Yeast clones that
successfully displaced the orotidine-5'-phosphate decarboxylase (URA3) gene with the
DNA fragment(s) of interest within the backbone pREC ΔGag–U3 vector grew on this
media. However, colonies that retain the URA3 gene do not grow as the URA3 gene
converts FOA in the media into fluorouracil, a toxic metabolite. Leucine dropout media
was used for additional auxotrophic selection to ensure the yeast colonies that grew
contained the pREC ΔGag–U3 backbone, which contained the beta-isopropylmalate
dehydrogenase gene (LEU2) for retention of transformed yeast when grown in the absence
of leucine. After 72h of growth at 30 ˚C, colonies were isolated and recombinant DNA was
isolated.

2.7 Yeast DNA Extraction
S. cerevisiae colonies that were grown on CSM–Leu+5-FOA plates were collected and
placed into an Eppendorf tube with 0.3g of 425–600 µm acid-washed glass beads (SigmaAldrich Canada). Into this, 200 µL of breaking buffer was added (2% v/v Triton X-100,
1% w/v sodium dodecyl sulphate solution, 100 mM NaCl, 10 mM pH 8.0 Tris-Cl, 1 mM
pH 8.0 EDTA). Once the yeast solution was completely homogenized, 200 µL of 24:25:1
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(v/v) phenol:chloroform:isoamyl alcohol was added to the mixture before vortexing for 2
minutes at 300 G. The solution was subsequently centrifuged at 18000 G before 50 µL of
the top aqueous layer containing DNA was extracted. Afterwards, 10% (w/v) 3M pH 5.2
sodium acetate solution was added to the solution with 100 µL of cold anhydrous ethanol
to precipitate the DNA. To pellet the DNA, the mixture was mixed well and incubated at
–20 ˚C for 20 minutes, before centrifuging at 18000 G for 12 minutes. The DNA pellet was
washed with 70% ethanol and centrifuged for 30 seconds at 18000 G before resuspending
in 30 µL of RNAse/DNAse-free H2O.

2.8 Transmission Electron Microscopy
As described previously158, HEK 293T cells transfected with VP or VLP were collected in
15 mL conical tubes and centrifuged at 175 G for 10 minutes to pellet the cells. Cells were
then washed with cacodylic acid (pH 6.5) before resuspending the cell pellet with 500 µL
of 2.5% (v/v) glutaraldehyde in sodium cacodylate. Cells were then centrifuged and
resuspended in 1% (w/v) osmium tetroxide in sodium cacodylate, and subsequently shaken
for 1h. To dehydrate samples, cell pellet was resuspended in 1 mL of increasing
concentrations (v/v) of acetone (30%, 50%, 70%, 90%, 95%, and 100%) for 10 minutes
each. Following these washes, the sample was serially resuspended in increasing amounts
of TEM Araldite Resin, while amount of acetone was reduced. This was continued until all
the acetone was completely replaced by the resin. Samples were baked at 60 ˚C for 48h to
solidify the resin. The samples were subsequently cut into 70nm thick sections using an
UltraCut UltraMicrotome (Sorvall). Slices were then mounted onto copper meshing and
stained with uranyl acetate. After allowing the samples to dry, they were stained with lead
citrate and subsequently washed with sterile water. Samples were subsequently air-dried
and imaged on a Phillips CM10 TEM machine.

2.9 In vitro Transcription of PCR Products to Generate RNA
Constructs
The RNA was amplified by PCR using primers containing the T7 RNA polymerase
promotor sequence. Resulting amplicons were used for downstream in vitro transcription
using a MEGAscript™ transcription kit (ThermoFisher, CA). As per manufacturer
instructions, a 20 µL reaction was assembled using 2µL of each ribonucleotide (ATP, CTP,

7

GTP, UTP) with 2 µL of 10X reaction buffer, 0.15 µg of PCR product template, and 2 µL
of the T7 enzyme mix. The reaction was incubated at 37 ˚C for 16 hours, to increase the
number of transcription initiation events required to synthesize large mass quantities of
RNA.

2.10 RNA Secondary Structure Prediction
RNA sequence was inputted to an online RNA prediction server, which combined four
structure prediction and analysis algorithms. Specifically, the partition function algorithm
determined the most probable base-pairing scheme for the RNA molecule. The minimal
free energy structure was subsequently calculated to determine an overall secondary
structure that minimizes the Gibbs free energy of a given RNA conformation. In addition,
the minimal free energy structure was compared to the RNA structure predicted by the
maximum expected accuracy model to generate the most likely secondary structure.
Finally, an algorithm detecting RNA pseudoknots was run before displaying the final
secondary structure.

2.11 Human PBMC Antigenicity Assays
2.11.1

Determining antigenicity of VP and VLPs

PBMC were isolated from healthy donors (n = 5) using density gradient centrifugation
(Milltenyi Biotec, CA). Cells were resuspended in RPMI before plating into 96-well plates
with 106 293T cells/well. Each well received 5 µg/mL (based on p24) of either VP or VLP.
Positive control wells were treated with either 10 µg/mL ORN02/LyoVec™, an AU-rich
oligonucleotide complexed with a lipid-based transfection reagent, or with 2 µL/mL of
PMA/Ionomycin cell stimulation cocktail (ThermoFisher Scientific, CA). Cells were then
incubated at 37 °C and 5% CO2 for 24h before collecting cell culture supernatant for
detection of TNFα by ELISA using manufacturer’s guidelines (Mabtech, USA). Briefly,
0.5 mg/ml mixture of anti-TNF3/4 mAb capture antibody (Mabtech, USA) was adsorbed
to each well of a high-binding 96-well microplate before blocking with 1X PBS + 0.05%
Tween® + 1% BSA overnight at 4 °C. On the following day, 100 µL of culture supernatant
from pulsed PBMC were loaded onto wells before incubating at room temperature for 2
hours and washing with 1X PBS + 0.05% Tween®. Subsequently, 1 µg/mL of biotinylated
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monoclonal antibody TNF5 was added before incubating for 1 hour and adding
Streptavidin-HRP diluted to 1:1000 and incubating for an additional hour.
The plate was washed before developing the ELISA reaction with 100 µL of
tetramethylbenzidine substrate solution (Seracare, Milford, MA). The reaction was stopped
with 1N H2SO4 and absorbance was read at 650nm using a spectrophotometer (BioTek,
USA).

2.11.2

Determining Antigenicity of RNA Constructs

PBMC from healthy donors (n = 5) were resuspended using density gradient centrifugation.
Cells were subsequently plated at 5 × 10' cells/well in a 96-well plate. After resting
PBMCs overnight, cells were transiently transfected with 5 µg of RNA using 10 µg/mL of
dioleoyl-3-trimethylammonium propane (DOTAP). Specifically, RNA was incubated with
DOTAP in incomplete RPMI for 15 minutes before adding into respective wells.

2.12 Latency Reversal Assays
Latency reversal assays were carried out as previously described (manuscript under
review). Briefly, PBMC were isolated from acutely infected HIV+ donor before enriching
resting CD4+ T lymphocytes using negative depletion CD4+ T cell isolation kit (Miltenyi
Biotec, USA). Autologous monocyte-derived dendritic cells (MDDCs) were generated by
plastic adherence of monocytes from the negative depletion filtrate. These cells were
cultured for six days in media supplemented with GM-CSF (1000 U/mL) + IL-4 (500
U/mL), as previously described 160. On the sixth day, MDDCs were pulsed with either VP
or VLP. For TLR stimulation experiments, MDDCs were treated with TLR agonists:
Imiquimod (1 µg/mL) or ssRNA40/LyoVec™ (5 µg/mL). Additional treatments involving
combinations of TLR agonist and VLP were also tested. The following day, CD4+ T cells
were co-cultured with pre-treated, autologous, pulsed MDDCs. To prevent de novo
infection of uninfected cells by reactivated latent virus, 10 µM of Enfuvirtide, a fusion
inhibitor, was added to the culture before incubating for 24 hours at 37 °C and 5% CO2.
Degree of latency reversal was determined as a function of amount of induced virus in
culture supernatant (measured by qRT-PCR detecting HIV RNA in cell-free supernatant),
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and T cell activation (measured by human IFN-γ, detected by enzyme-linked
immunosorbent assay (ELISpot) assay.
IFN-γ ELISpot was used to quantify T cell activation. Plates containing pre-coated layer
anti-IFN-γ antibodies were washed with PBS before blocking for 30 minutes with complete
RPMI. Following a wash step, the MDDC-pulsed CD4 T cells were plated at 1 × 10%
cells/mL and incubated for 16h at 37 °C and 5% CO2. Wells containing unstimulated T
cells in complete RPMI media served as negative controls. Biotinylated anti-IFN-γ
antibody was added at 1 μg/ml for 2h and subsequently washed and incubated with
streptavidin-HRP for 1h. To detect spots, 100 µL of TMB substrate was added to each well
after thoroughly washing plates with PBS.

2.13 Quantifying Packaged RNA within HIV Particles
To quantify the amount of packaged RNA within particles, viral RNA from culture
supernatant was isolated using a QIAamp Viral RNA Mini Kit (Qiagen, USA). First-strand
cDNA synthesis was subsequently performed using SuperScript III First-Strand Synthesis
System for RT-PCR (Invitrogen, CA), according to manufacturer instructions. The cDNA
was stored at -20°C or used immediately for 2-step qRT-PCR. Irrespective of which primer
set was employed, reactions were assembled with 10 µL of 2X PowerUp™ SYBR™ Green
Master Mix, 500 nM primers, and 1 μL of cDNA template. Final reaction volume of 20 μL
was achieved with the addition of water before being run on a QuantStudio 5 RT-PCR
system. To detect viral genomic RNA, a Gag-specific primer set (GagF + GagR) was
employed, whereas recrudescent virus in latency reversal assays were detected using
5’LTRPA, a primer landing on the 5’ LTR. To detect RNA adjuvants, unique barcodespecific primer sets–located within the RNA adjuvant constructs–were employed. The
qRT-PCR reaction was carried out by holding temperature at 50°C for 2 minutes for uracilN-glycosylase activation, followed by a 95°C incubation for 2 minutes for DNA
polymerase activation. Forty cycles of PCR were subsequently carried out, where each
cycle consisted of a denaturing phase at 95°C for 15 seconds, an annealing phase at 60˚C
for 15 seconds, and an extension phase at 72˚C for 1 minute. Copies of RNA were then
normalized to p24 levels.
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2.14 Statistical Analyses
Statistical analyses were performed using GraphPad Prism version 8.0 (GraphPad
Software, San Diego, CA). A statistically significant difference was defined when the P
value was <0.05 by paired Student’s t test, unpaired Student’s t test, or Friedman test
with Dunn’s multiple comparisons tests.
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Chapter 3 - Results

3.1 Co-formulating HIV VLP with Exogenous TLR7 Adjuvant,
ssRNA, Augments HIV-1 Latency Reversal
In a subset of memory CD4+ T cells within infected donors, HIV persists as a stably
integrated provirus. Although most proviruses are defective, a subset of memory CD4+ T
cells harbor fully-intact replication competent provirus, and constitute the majority of the
latent reservoir161. To date, it has been impossible to distinguish cells harboring latent HIV
from uninfected cells. Our research team has previously hypothesized that the latent
reservoir might preferentially reside within resting memory CD4+ T cells bearing TCRs
specific for HIV antigens. This may be especially true during acute HIV infection where
responding CD4+ T cells are at increased risk of infection due to their activated state. If
this hypothesis is true, reactivation of these cells through the TCR using HIV antigens may
allow for transcriptional reactivation of the proviral reservoir162. Previous data from our
lab suggests that our VLPs immunotherapy, which displays HIV antigens from the
reconstructed quasi-species of five HIV infected individuals, induces greater latency
reversal than clinically relevant latency reversal agents (manuscript under review). At the
same time, several published studies have described the latency reversal potential of certain
TLR agonists in cell lines and primary cells138,163,164. In particular, the capacity of TLR7/8
agonists to induce latency reversal in vitro has been well described165–169.
As our research team has data to support VLP-mediated latency reversal, we hypothesized
that adding in an exogenous adjuvant to the VLP formulation might enhance the latency
reversal and overall T cell activation that we detect in our latency reversal assays.
Therefore, we chose to adjuvant our VLP formulations with TLR agonists to determine
whether the observed VLP-mediated latency reversal could be increased. Various
combinations of TLR ligands were added to VLP formulations, including
polyinosinic:polycytidylic acid (polyI:C), Imiquimod, and ssRNA which activate TLR3,
TLR7, and TLR8 respectively. CD4+ T cells were purified from whole PBMC isolated
from HIV– or HIV+ donors. Autologous MDDCs were then pulsed with VLP in the
presence or absence of TLR agonists (Fig 7A). MDDCs were then co-cultured with CD4+
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T cells at a ratio of 1:4. Copies of genomic RNA from induced virus was quantified by
qRT-PCR, which utilized an optimized primer set and qRT-PCR assay that binds to the 5’
LTR158. The ability of the qRT-PCR assay to discriminate RNA from induced virus as
opposed to nucleic acids associated with the VLPs used to pulse MDDC is based on three
properties: 1) our latency reversing VLPs that are pulsed into MDDCs are genomeless and
therefore do not contain packaged RNA, 2) the VLPs have a mutagenized integrase enzyme
and therefore cannot perform integration, and abrogates RNA genome packaging170 and 3)
the plasmid DNA of the VLP constructs lack a 5’ LTR preventing any potential for reverse
transcription, which precludes RNA genome packaging. T cell activation was measured by
commercially available IFN-𝛾 ELISpot.
CD4+ T cells from HIV+ donors that were co-cultured with MDDCs pulsed with either
VLP alone or with Imiquimod induced detectable levels of HIV-1 RNA in culture
supernatants, however was not significantly different from unstimulated media control. In
contrast, MDDCs treated with Poly(I:C) or ssRNA induced significantly higher HIV RNA
than unstimulated media control. MDDCs pre-treated with Poly(I:C), Imiquimod, or
ssRNA before pulsing with VLP were all able to induce significantly higher HIV RNA
from CD4 T cells than unstimulated media control (Fig 7B). With respect to T cell
activation, there was no statistically significant difference between IFN-γ secretion from T
cells after co-culturing with MDDCs pulsed with either VLP alone or pre-treated with
Poly(I:C) or Imiquimod. However, when T cells were co-cultured with MDDCs that were
pre-treated with ssRNA, it induced significantly more IFN-γ than unstimulated media
control. Likewise, T cells released significantly higher IFN-γ in response to co-culturing
with MDDCs pulsed with a combination of ssRNA + VLP, Imiquimod + VLP, and
Poly(I:C) + VLP (Fig 7C).
To demonstrate that the HIV RNA that was measured in our latency reversal assays was
specific for induced virus and not from our VLPs, we quantified viral RNA in culture
supernatants from MDDC-CD4 T cell co-cultures derived from HIV negative donor
PBMC. This also enabled us to evaluate the antigenicity of the VLPs and TLR agonists in
healthy donor samples, thereby verifying that the stimuli used were immunostimulatory.
As expected, no HIV RNA was detected in the negative control culture conditions where
MDDCs from healthy donors were pulsed with VLP alone or pre-treated with TLR
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agonists, before co-culturing with autologous T cells. Likewise, MDDCs treated with
various combinations of VLP and TLR agonists did not induce detectable HIV RNA in
culture supernatant after co-culturing with autologous T cells (Fig 7D). This suggested that
the assay was detecting induced virus and that the VLPs were not being detected in this
system. MDDCs from HIV– donors treated with Poly(I:C) induced significantly higher
IFN-γ secretion from co-cultured T cells, whereas MDDCs treated with Imiquimod or
ssRNA did not induce a statistically significant difference in IFN-γ secretion from cocultured T cells. Interestingly, MDDCs pulsed with combinations of VLP and TLR
agonists were able to induce IFN-γ secretion from T cells; however, these phenomena were
not statistically significant (Fig 7E). Taken together, these results suggest that VLPmediated latency reversal may be enhanced by the inclusion of TLR agonists such as
ssRNA.
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Figure 7. Adjuvanting VLPs with exogenous ssRNA augments latency reversal
Human PBMC from HIV+ donors (n = 4) or HIV– donors (n = 5) were used to isolate CD4
T cells, which were subsequently stimulated with autologous monocyte-derived dendritic
cells (MDDCs) pulsed with combinations of VLP and TLR agonists. T cell activation
measured by ELISpot IFN-γ spot forming units (SFU) per 106 CD4 T cells. Copies of
recrudescent virus measured by qRT-PCR, which employed a primer set that targets the
HIV 5’ LTR. (A) Experimental timeline and flow. (B) Copies of recrudescent virus
released from T cells isolated from HIV+ PBMC. (C) IFN-γ secretion from T cells isolated
from HIV+ PBMC. (D) Copies of recrudescent virus released from T cells isolated from
HIV– PBMC. (E) IFN-γ secretion from T cells isolated from HIV– PBMC. Results are
presented as mean ± SEM of HIV copy number or IFN-γ SFUs. Student’s t tests were
performed to compare results to unstimulated media control. *p<0.05.
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3.2 VPs containing packaged viral genomic RNA were
more antigenic than packaging-deficient VLPs
During the construction of our latency reversing VLP formulations, we purposefully
constructed formulations that would not contain HIV genomes. This was done for safety
reasons and with one eye on future testing in non-human primates and eventually in human
clinical trials. Since our previous data suggested that TLR agonists, like ssRNA could
augment VLP antigenicity, we hypothesized that by eliminating the ability of the HIV
genome from packaging in our VLPs, we might have inadvertently reduced the latency
reversal potential of our VLP formulations. Therefore, we sought to identify the antigenic
contribution of packaged HIV RNA within viral particles (VP) and compare it to our VLP
formulations. To do this, we generated a novel particle construct, encoding a VP-generating
vector with the ability to package its own defective genome i.e. with a functional y and
without the ability to reverse transcribe (D 5’LTR) or have functional integrase. This VP
formulation was then evaluated against the previously made VLP-encoding vector which
contained a severely mutated Ψ (preventing RNA packaging) and without the ability to
reverse transcribe (D 5’LTR) or have functional integrase. It is therefore important to note
that apart from the abilities to package or not package their respective RNAs, the VPs and
VLPs are structurally and proteomically identical (Fig 8A).
To characterize the particles that were produced from both constructs, TEM was first
performed to visually assess the structure and size of the generated particles. The VPs and
VLPs that were produced from HEK 293T were morphologically identical to each,
displaying an immature virion phenotype and a size of ~120 nm (Fig 8B). To assess the
quantity of packaged RNA within VPs and VLPs, viral RNA was extracted from lysed
particles and cDNA was synthesized using random hexamers. Following this, qRT-PCR
was used to quantify the amount of packaged RNA using a primer set specific for HIV
Gag. Copies of RNA were subsequently normalized to p24. Quantity of packaged RNA in
VLP was then expressed as a percentage of packaging compared to VPs. Although both
VP and VLP constructs produced morphologically similar particles, VLPs contained 21%
of packaged RNA compared to VPs, which was a statistically significant difference
(p<0.0001). No HIV RNA could be detected in media devoid of VP or VLP (Fig 8C).
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As mentioned previously, single stranded RNA is a known TLR7 agonist. Therefore, its
presence in VPs should increase their abilities to trigger innate antiviral immune responses.
To assess if there were any antigenic differences between the VPs and VLPs due to the
presence or absence of packaged RNA, PBMCs from healthy donors (n = 5) were cocultured with VPs or VLPs for 24h, 48h, or 72h. A global T cell activator, phorbol 12Myristate 13-Acetate/Ionomycin (PMA/Iono), was used as an assay positive control. A
TLR7/8 agonist, ORN02/LyoVec™, which is an AU-rich oligonucleotide complexed with
a lipid-based transfection reagent, was also employed as an additional assay control. As
shown, the VPs induced significantly greater TNFα (455 pg/ml) production in PBMCs than
VLPs (84 pg/ml) after culturing for 24h and then again after 48h (p<0.05); however, the
levels of TNFα- in some samples were below the sensitivity of the assay by 72h (p≥0.05),
indicating there is a short 48h window in which to detect TNF-α production from human
PBMC (Fig 8D). These results collectively suggest that virally packaged RNA in VPs is
more immunostimulatory than VLPs without encapsidated RNA.
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Figure 8. VPs containing packaged viral genomic RNA are more immunostimulatory
than packaging-deficient VLPs.
VPs and VLPs were generated by transfecting VP-encoding constructs or VLP-encoding
constructs into HEK 293T cells for 72 hours (A). After purifying virus through
ultracentrifugation, structural integrity of particles was interrogated using TEM (B), and
packaged genomic material was quantified by qRT-PCR (C). Scale bars are 100 nm.
PBMCs from healthy donor (n = 5) were subsequently stimulated with 5 µg/mL VP, 5
µg/mL VLP, 5µg ORN02, or 1X PMA/Ionomycin. Cell activation was measured as a
function of TNF-α in culture supernatant 24h, 48h, and 72h post-stimulation (D). Data
are represented as mean ± SEM. An unpaired Student’s t test was used to compare
packaging between VP and VLPs, whereas a paired Student’s t test was used to compare
TNF-α induction in PBMCs stimulated with either VP or VLP. ****p<0.0001, *p<0.05.
Ψ; HIV packaging signal.

3.3 VPs induce greater latency reversal than VLPs in HIV+
PBMCs
Since VPs were more immunostimulatory than VLPs in cultures of healthy human PBMCs,
we sought to characterize, if any, the effect of packaged viral RNA on latency reversal. To
do this, PBMCs were isolated from HIV+ donors (n = 6) and latency reversal assays were
carried out as described in Fig 9A. Briefly, VPs or VLPs were used to pulse MDDCs from
HIV+ PBMC and then co-cultured with autologous CD4 T cells. Latency reversal was
measured as a function of T cell activation and induced HIV copy number in culture
supernatants. As shown (Fig 9B), significantly more IFN-γ was released from T cells that
were co-cultured with MDDCs pulsed with VPs compared to VLPs in all 6 donors
(p<0.05). Although elevated concentrations of HIV RNA were detected in culture
supernatants from cells derived from 4/6 donors, this was not statistically significant (Fig
9C). Despite the lack of statistical significance, there may be some biological significance
for HIV cure due to the low frequency of latently infected cells. Additionally, the VLPs
are a heterologous formulation to the virus that infected the CD4 T cells, meaning the
MDDC presented peptides might not be a perfect match for T cell activation in all cases.
As a result, small changes in the data, albeit not statistically significant, could have some
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biological significance. Alternatively, it is possible in the two donors in which no increase
in HIV RNA was detected, that the VLPs had reactivated the entirety of the reservoir from

the cells. Collectively, the results suggest that virally packaged HIV RNA is capable of
augmenting both particle antigenicity and potential of latency reversal.
Figure 9. VPs induce greater latency reversal than VLPs in HIV+ PBMCs.
CD4 T cells from HIV+ PBMC (n = 6) were stimulated with autologous MDDCs pulsed
with either VP or VLP (A). CD4 T cell activation was measured by ELISpot as a function
of IFN-γ SFUs per 106 CD4 T cells (B), whereas copies of recrudescent virus were
measured by qRT-PCR employing a primer set that bound to the 5’ LTR (C). Data are
displayed as mean values and each line represents matched responses from each donor.
*p<0.05 using paired Student’s t test.
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3.4 Design of packaging-competent immunostimulatory
RNA adjuvants to replace HIV genomic RNA in VPs
Although the packaging of RNA into VPs can significantly increase the T cell stimulatory
capacity of the formulation when presented by MDDC, the increase in amount of HIV
RNA that was detected in culture supernatants was not statistically significant compared
to the VLP formulation. This is despite increasing the detectable HIV RNA in culture
supernatants in most samples tested (4/6 donors). These results suggest that the inclusion
of an RNA component into the VLP formulation can enhance its latency reversal properties
and therefore enhance the overall efficacy as an LRA. This is especially true given all
inducible proviruses must be extracted from the cellular reservoir in order to achieve a
sterilizing cure. Hence even a non-significant increase in the detected HIV RNA upon
latency reversal is likely to have biological significance. Therefore, we hypothesized that
incorporating a safe adjuvanting RNA, with the potential to trigger and augment proviral
transcriptional reactivation from the cellular reservoir, may increase the efficacy of VLPs
as a potential immunotherapeutic strategy for HIV cure. With this in mind, we constructed
adjuvanting RNAs with the capacity to be packaged within VLPs.

To do this we

synthesized RNAs based on “GC” and “AU” rich content as they had previously been
shown to preferentially induce IFN-α and TNF-α biased cytokine profiles based on their
sequence specificity for TLR7 and TLR8171.
Using these GU and AU rich motifs, we designed a packaging-competent
immunostimulatory DNA vector, which could be transcribed in vivo by utilizing a CMV
promotor. In addition, the inclusion of an upstream T7 RNA polymerase promotor enabled
in vitro transcription. A cis-acting packaging signal was then designed upstream of the
immunostimulatory region and downstream of the CMV promotor, allowing ssRNA to be
packaged into VLPs upon co-transfection with the VLP-encoding vector to produce
adjuvanted VLPs. Three RNA adjuvants were generated, and each differed in GU or AU
content. These include a Multi RNA adjuvant containing repeat motifs of two “GC”-rich
domains: (GUUC)25 + (GUCC)25, and two “AU”-rich domains: (AUGU)25 + (UAUU)25.
Single adjuvants expressing either, (GUUC)25, or (AUGU)25 were also made (Fig 10A–C).
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To determine the structure of these RNA adjuvants, positional entropy was calculated for
each nucleotide and used as a basis to calculate the most energetically favorable structure
using an in silico RNA folding algorithm172. All RNA adjuvants were determined to have
favorable folding entropies with ∆G < 0. The Multi adjuvant had the most favorable folding
entropy at -250.30 kcal/mol, followed by the GUUC adjuvant (-193.60 kcal/mol). The
AUGU adjuvant, had the least favorable folding entropy of the three at -182.00 kcal/mol.
Interestingly, there were some regions in the adjuvants where positional entropy
approached +4.4 J/K in the Multi (Fig 10A) and GUUC (Fig 10B) RNA adjuvants, whereas
the AUGU RNA adjuvant had a stretch of 3 nucleotides whose positional entropy
approached +2.2 J/K (Fig 10C). Since the positional entropies are greater than 0 kcal/mol,
it signifies that these stretches of nucleotides are in unfavorable conformations. However,
the packaging signal for all adjuvants were clearly marked by two stem loop structures,
characteristic of SL1 and SL2, which are the stem-loop structures found in Ψ that confer
RNA packaging.
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Figure 10. Design of Packaging-competent RNA Adjuvants.
Above each of the predicted structures is the schematic of the DNA vector used to
generate the RNA adjuvants. The length of each immunostimulatory domain is given by
the subscripted number in the schematic above each RNA fold structure. The blue
highlight region downstream of the CMV promotor and upstream of Ψ in each of the
adjuvant corresponds to a 5’ LTR deletion. The predicted structure is color-coded based
on the positional entropy of each nucleotide. The HIV packaging signal is highlighted in
green. Predicted structure of (A) Multi (B) GUUC and (C) AUGU adjuvants are shown.
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3.5 Addition of DOTAP to RNA adjuvants generates particles
After generating DNA vectors that encoded the immunostimulatory RNAs, we sought to
characterize its innate antigenicity. To do this, linear RNA adjuvant fragments were
generated through in vitro transcription of the RNA adjuvant DNA vector. Briefly, a 5’
primer that contained a T7 RNA polymerase promotor site was used in conjunction with
a 3’ primer that bound to the HIV 3’ LTR. The resulting linear fragments of DNA were
subsequently used for in vitro transcription using T7 RNA polymerase to generate linear
RNA adjuvant fragments. These oligoribonucleotides were subsequently complexed
within cationic lipoplexes capable of delivering the RNA into cells. This was done by
incubating RNA adjuvants with the cationic lipid dioleoyl-3-trimethylammonium
propane (DOTAP). To ensure that RNA-lipid complex formation had taken place, and to
characterize the particles, we measured the size distribution profile for each complex
using dynamic light scattering (DLS). As shown in Fig 11, the sizes of GUUC, AUGU,
and Multi RNA in complex with DOTAP were significantly smaller than DOTAP alone
(p<0.0001), indicating a successful condensation reaction. The sizes of RNA in the
absence of DOTAP was also measured and was determined to be significantly smaller
(p<0.0001) than complexes generated with DOTAP. This result suggests that the RNA
adjuvants can form nanomolecular complexes with DOTAP. There was no discernable
difference between the differing RNAs to successfully form lipoplexes. Interestingly all
generated lipoplexes had a size range of 159 – 170 nm, which is only slightly larger than
the size ranges of HIV-1 virions.
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Figure 11. Sizes of DOTAP cationic liposome particles with RNA adjuvants.
RNA adjuvants were first generated by in vitro transcription using T7 polymerase.
Liposomal particles were generated by incubating 10 µg/mL of DOTAP with 5 µg of
RNA. Particles were then diluted 100-fold, before loading 10 µL of the prepared sample
into a dynamic light scattering device capable of characterizing particle size distribution.
Data are representative of twenty independent read events and are expressed as means ±
SEM. ****p<0.0001 by unpaired Student’s t test.

3.6 RNA adjuvants are immunostimulatory and trigger IRF
and NF-κB responses in a THP-1 Dual reporter cell line
Before making adjuvanted particles with encapsidated RNA, we evaluated the ability of
the various RNA adjuvants to induce immune activation by measuring their ability to
activate key transcription factors. Both interferon regulatory factor (IRF) and NF-κB are
key signaling molecules which are heavily involved in enacting innate antiviral immune
responses and inflammation173. To test the RNA adjuvants, the various adjuvanting
RNAs were complexed with DOTAP to form lipoplexes as previously described. The
lipoplexes were then used to stimulate THP-1 Dual™ cells, which express Luciferase and
SEAP under the control of NF-kB and IRF. In this reporter cell line, the Lucia luciferase
reporter gene is under the control of the ISG54 minimal promotor with five additional
IFN-stimulated response elements while the secreted alkaline phosphatase reporter gene
is driven by five copies of the NF-κB consensus transcriptional response elements with
three c-Rel binding sites. The IRF pathway activation was determined as a function of
Lucia luciferase activity (relative light units, RLU) in culture supernatant, whereas NFκB pathway activation was determined as a function of alkaline phosphatase levels. As
assay positive controls, PMA/Iono, GS-9620, and imiquimod were used to stimulate the
reporter cells.
All lipoplex formulations using the various RNA adjuvants induced significantly higher
IRF activation compared to uncomplexed RNA (p<0.0001) or the unstimulated media
control (p<0.0001) (Fig 12A, B). Specifically, the multi RNA adjuvant, although 191-fold
more immunostimulatory than the media control, induced the least IRF activation
compared to the AU-rich and GU-rich RNA adjuvants. In contrast, the AU RNA adjuvant
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induced the greatest IRF activation (609407 ± 63038 RLU). Lastly, the GU RNA adjuvant
induced 434545 ± 62001 RLU. Comparatively, minimal activation of the IRF pathway
was detected when PMA/Iono, GS-9620, and Imiquimod were used as positive control
stimulations.
All RNA adjuvants induced significantly higher NF-κB activation when complexed to
DOTAP, whereas the RNAs alone did not activate NF-κB (Fig 12C). The multi RNA
adjuvant complexes induced the least NF-κB activation (OD 0.45 ± 0.02321). The
antigenicity of the multi RNA complexed to DOTAP is significantly greater than the multi
RNA alone (p<0.01). The AU RNA adjuvant complexes induced the greatest NF-κB
activation, at OD 0.9 (± 0.1186). When complexed to DOTAP, the AU RNA adjuvant was
also significantly more antigenic than the AU RNA alone (p<0.0001). The GU RNA
adjuvant complexes induced OD 0.54 (± 0.07449). The GU adjuvant in complex to
DOTAP was significantly more antigenic than GU RNA alone (p<0.01). These trends
persisted when these data were represented as fold increases over media control (Fig 12D).
The positive controls did induce greater, but non-significant elevations in the levels of NFκB when compared to the media control with only with PMA/Iono inducing significantly
greater NF-κB activation compared to media alone (p<0.0001); however, for GS-9620 and
Imiquimod, this phenomenon was not statistically significant. Taken together, the results
suggest that the RNA adjuvants are immunostimulatory and result in NF-kB activation.
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Figure 12. RNA adjuvants are antigenic and trigger IRF and NF-κB responses in a
THP-1 Dual Reporter cell line.
THP-1 Dual™ cells (105 cells/well) were stimulated in a 96-well plate format with 5µg
RNA adjuvant or with positive controls: 1x PMA/Iono, 2µM GS-9620, or 2 µg/mL
Imiquimod. Results are from three independent experiments. Cells were cultured for 24h
at 37 °C and 5% CO2 before assessing IRF and NF-κB activation. Specifically, IRF
activation was assessed as a function of Lucia luciferase in culture supernatant (A). Data
were represented as fold increase over media (B). In parallel, NF-κB activation was
assessed as a function of secreted embryonic alkaline phosphatase levels in culture
supernatant, which was measured by absorbance readings at 630 nm (C). Data were
represented as fold increase over media (D). Data are shown as means ± SEM. Unpaired
Student’s t tests were used to compare groups to media control. **** p<0.0001. **p<0.001.
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3.7 RNA Adjuvants Trigger Differential TNF-α and IFN-α
responses in human PBMCs
As we had previously evaluated the various RNA constructs in the THP-1 model cell lines,
we subsequently sought to confirm the antigenicity of the various RNA adjuvants in a more
biologically relevant cell type. Therefore, PBMCs from HIV– donors (n = 5) were
stimulated with RNA adjuvants complexed to DOTAP and assessed for their secretion of
IFN-α and TNF-α. In addition, PBMCs were stimulated with PMA/Iono, GS-9620, and
Imiquimod, all serving as positive assay controls. Donors had varying IFN-α responses to
the RNA adjuvants and positive controls (Fig 13A). When these IFN-α responses were
represented as a mean value across the five donors, several trends became apparent.
Specifically, the GU RNA adjuvant induced significantly greater IFN-α induction
compared to media control (p<0.0001). In fact, the GU RNA adjuvant induced the greatest
IFN-α production compared to any of the other RNA adjuvants. The AU RNA adjuvant
also induced significantly greater IFN-α induction compared to media control (p<0.01).
The multi RNA adjuvant induced the least IFN-α production and was significantly different
from media control (p<0.05) (Fig 13B). For comparison, the multi RNA adjuvant and the
AU RNA adjuvant induced 42% and 55%, respectively, of the IFN-α response elicited by
the GU RNA adjuvant.
Donors had varying TNF-α responses towards the RNA adjuvants and positive controls
(Fig 13C). When responses were expressed as means of the five donors, it became apparent
that the AU RNA induced the most TNF-α secretion from PBMCs and was significantly
greater than the media control (p<0.0001). However, the TNF-α induction using the other
RNA adjuvants were not statistically different compared to the media control. Specifically,
the TNF-α responses elicited by the multi RNA and GU RNA was only 22% and 28%,
respectively, of the response elicited by the AU RNA (Fig 13D).
To determine if the RNA adjuvants had preferential biases towards stimulating an IFN-α
or a TNF-α response, the ratio of TNF-α secretion to IFN-α secretion for each RNA
adjuvant was determined (Fig 13E). It was apparent that the responses between the AU
RNA and the GU RNA adjuvants were statistically different (p<0.005). Specifically, the
AU RNA adjuvant induced the highest ratio of TNF-α to IFN-α, whereas the GU RNA
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adjuvant induced the lowest ratio of TNF-α to IFN-α. There was no statistically significant
difference between the ratio of TNF-α to IFN-α induced by the multi RNA compared to
either the GU or the AU RNA adjuvants. These results suggest that the sequence identity
of the RNA adjuvants was capable of skewing immune responses, resulting in a bias
towards either a TNF-α predominant response, or an IFN-α predominant response.
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Figure 13. RNA Adjuvants Trigger Differential TNF-α and IFN-α responses from
human PBMCs
PBMCs from healthy donors (n = 5) were plated in a 96-well plate format at 5 × 10'
cells/well. Cells were then stimulated with RNA adjuvants (5 µg) complexed to DOTAP,
or with positive controls GS-9620 (2 µM), PMA (40.5 µM) + Ionomycin (670 µM),
Imiquimod (2 µg/mL). After 24h, supernatant was collected to determine IFN-α and TNFα levels using an ELISA. Bar graph showing individual donor IFN-α responses to the
treatment conditions (A). Bar graph showing mean IFN-α responses towards each
condition (B). Bar graph showing donor TNF-α responses to treatment conditions (C). Bar
graph showing mean TNF-α responses towards treatment conditions (D). Bar graph
showing ratio of TNF-α secretion to IFN-α for each RNA adjuvant (E). Results are
represented as mean of 3 independent experiments ± SEM. ****p<0.0001, **p<0.005,
*p<0.05 by Friedman test followed by Dunn’s multiple comparisons tests.
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3.8 Co-administration of RNA adjuvants increases VLP
antigenicity in THP-1 cells
In the most probable future scenario, the RNA adjuvants would be packaged into VLPs for
safe delivery and to increase its specificity. However, we sought to initially determine
whether co-delivery of RNA adjuvants and VLPs was more antigenic than HIV RNA found
in VPs. This was done to evaluate the potential of the RNA adjuvants as potential codelivered adjuvants, should downstream processes that involve packaging RNA adjuvants
into VLP became problematic. To do this the THP-1 reporter cell line was cultured with
either VP, VLP, or VLP in the presence of each RNA adjuvant. In addition, cells were
cultured with Imiquimod or GS-9620 as positive controls. After culturing for 24 hours, IRF
and NF-κB activation was characterized as described previously. As shown in Fig 14A,
VLPs that were co-administered with RNA adjuvants induced significantly more IRF
activation (p<0.0001) than VPs containing HIV RNA. This phenomenon was consistent
for each RNA adjuvant (GU, AU, and Multi). On average, the IRF response to VLP + RNA
adjuvant was 97-fold greater than VPs. Likewise, Fig 14B shows that VLPs coadministered with RNA adjuvants were significantly more capable of activating NF-κB
than VPs containing HIV RNA (p<0.05). On average, the NF-κB response to VLP + RNA
adjuvant was 9-fold greater than VPs. Interestingly, in both cases, VPs were significantly
more antigenic than VLPs (p=0.0249 for NF-κB, and p=0.0068 for IRF), which aligned
with our previous results.
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Figure 14. Co-administration of RNA adjuvants increases VLP antigenicity
THP-1 Dual™ cells were plated at 5 × 10' cells/well and stimulated with 5 µg of VP or 5
µg VLP, or 5 µg of RNA adjuvants complexed to DOTAP as previously described. After
24 h, cells were assessed for IRF and NF-κB activation by interrogating cell culture
supernatants for Lucia luciferase (A) and SEAP (B), respectively. Results were obtained
from two independent experiments. Values are represented as means ± SEM.
****p<0.0001, **p<0.005, *p<0.05 using unpaired Student’s t tests.
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3.9 Pharmacodynamic inhibition of RNA adjuvant-mediated
IRF and NF-κB activation
To characterize a potential mechanism through which the RNA adjuvants elicit IRF and
NF-κB activation, we sought to determine the effect of various TLR inhibitors on THP-1
Dual cell activation in response to RNA adjuvants and well-described TLR7 agonists , GS9620 and Imiquimod.. To do this, we used synthetic oligodeoxynucleotides (ODN) that
have been shown to specifically block TLR recognition of nucleic acids by competitively
inhibiting signaling through TLR7 (IRS-661), or both TLR7 and TLR8 (IRS-954). In
addition, we used chloroquine, which is a well-described molecule derived from quinoline.
As a lysosomotropic agent, chloroquine preferentially accumulates within endosomes and
inhibits TLR signaling through several concerted efforts. Since TLR signaling requires
endosomal acidification, chloroquine-mediated inhibition of endosomal acidification
effectively mitigates TLR activation. In addition, chloroquine binds to endosomal nucleic
acids and occludes TLR-binding epitopes.
In these inhibitor studies we observed that IRF activation in response to the positive
controls were significantly lower in the presence of IRS-661, IRS-954, or chloroquine,
compared to cells that were not treated with inhibitors (Fig 15A). Likewise, NF-κB
activation induced by the positive controls were significantly lower for cells that were pretreated with IRS-661, IRS-954, or chloroquine, compared to cells that were not pre-treated
with inhibitors (Fig 15B). IRF responses to the RNA adjuvants complexed to DOTAP were
significantly lower when cells were pre-treated with IRS-661, IRS-954, or chloroquine,
compared to untreated cells (Fig 15C). Interestingly, IRS-661 and IRS-964 pre-treatment
was unable to inhibit NF-κB activation for all three RNA adjuvants. However, pretreatment with chloroquine seemed to inhibit NF-κB secretion. Even so, this phenomenon
was only statistically significant for the AU RNA (Fig 15D). This suggests that the
stimulatory activity of the RNA adjuvants depends on several independent intracellular
recognition pathways.
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Figure 15. IRF activation, but not NF-κB activation, induced by RNA adjuvants can
be inhibited by IRS-661 and IRS-954.
To characterize the molecular targets responsible for recognizing the RNA adjuvants, THP1 Dual cells were pre-treated for 1 h with TLR inhibitors IRS-661, IRS-954, or chloroquine
(CQ). Cells were then stimulated with RNA adjuvants or positive controls (GS-9620 or
imiquimod). After 24 hours, cellular activation was interrogated. (A) IRF responses and
(B) NF-κB responses for positive controls. (C) IRF responses and (D) NF-κB responses
for RNA adjuvants. Results are representative of three independent experiments. Bars
represent means ± SEM. *p<0.05, **p<0.005, ***p<0.001, ****p<0.0001 using unpaired
Student’s t tests.
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3.10 RNA adjuvants can be selectively packaged into HIV
VLPs
After characterizing the Multi, GU, and AU RNAs and their antigenicity in THP-1 Dual
cell lines and in human PBMCs, we sought to determine whether these RNAs could be
selectively packaged into HIV VLPs in place of HIV genomic RNA. To do this, HEK 293T
cells were transfected with each packaging-competent RNA adjuvant. The following day,
the same cells were transfected with the VLP-encoding vector, which had a deficient
packaging signal. Cells were then incubated for 72 hours and adjuvanted VLPs were
purified by ultracentrifugation (Fig 16A). Of note, the yields from adjuvanted VLPs are
much lower than those of VLPs due to co-transfection of two plasmids as opposed to one.
Before assessing whether the particles contained packaged RNA adjuvant, we ensured that
the barcode sequences flanking the immunostimulatory regions could successfully be used
for detection in a qRT-PCR assay as shown in the schematics in Fig 16B – D. To this
extent, 100 ng of RNA adjuvant DNA vector was serially diluted 10-fold, and each dilution
was assessed for its ability to be detected through qRT-PCR. The multi adjuvant remained
detectable until 1 × 10,- ng dilution. A line of best fit across the mass of multi adjuvant
DNA vector in each dilution had a goodness of fit measured at R2 = 0.96 (Fig 16B) when
graphed against respective cycle threshold (Ct) values. The GU adjuvant remained
detectable until 1 × 10,' ng dilution. The line of best fit across the mass of GU adjuvant
DNA vector in each dilution of this adjuvant had a goodness of fit measured at R2 = 0.99
(Fig 16C) when graphed against respective Ct values. Lastly, the AU adjuvant had the least
sensitivity of detection and could only remain detectable until the 1 × 10,. ng dilution.
The line of best fit across the mass of AU adjuvant DNA vector in each dilution for this
adjuvant had a goodness of fit measured at R2 = 0.98 (Fig 16D) when graphed against
respective Ct values.
After verifying the ability of the RNA adjuvants to be detected by qRT-PCR and assessing
their respective parameters of detection sensitivity, we sought to compare the amount of
packaged RNA adjuvant in each of the adjuvanted VLPs. To this extent, RNA was
extracted from adjuvanted VLPs and cDNA was synthesized. In parallel, the same process
was carried out for HIV VLPs. We observed that the multi VLPs contained significantly
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more multi RNA compared to HIV VLPs (Fig 16E). Similarly, AU VLPs contained
significantly more AU RNA than HIV VLPs (Fig 16F). GU VLPs likewise contained
significantly more GU RNA than HIV VLPs (Fig 16G). These results suggest that the
delivery of RNA adjuvants can be selectively targeted by packaging into VLPs.
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Figure 16. RNA adjuvants can be selectively packaged into HIV VLPs.
To generate adjuvanted VLPs, HEK 293T cells were co-transfected with 5 µg/mL VLPencoding vector and 5 µg/mL RNA adjuvant-encoding vector. After incubating for 72 h at
37 ˚C and 5% CO2, particles were purified from culture supernatant following
ultracentrifugation (A). Viral RNA was extracted, and cDNA was synthesized, which was
subsequently used in qRT-PCR reactions utilizing primers that bound specifically to
individual RNA adjuvants shown in the colored arrows in B-D. The detection sensitivity
of Multi RNA adjuvant (B), GUUC RNA adjuvant (C), and AUGU RNA adjuvant (D) was
determined for qRT-PCR reactions. The amount of packaged RNA adjuvant was then
determined using qRT-PCR and subsequently normalized to p24 (E-G). Results are
representative of two independent experiments. Bars are depicted as means ± SEM.
*p<0.05, **p<0.005 using paired Student’s t tests.

3.11 Multi adjuvanted VLPs are more antigenic than HIV
VLPs
To determine whether adjuvanted VLPs were more antigenic than HIV VLPs, multi
adjuvanted VLPs and HIV VLPs were generated as previously described. Briefly, HEK
293T cells were co-transfected with a VLP-encoding vector and Multi RNA-encoding
vector. HIV VLPs were generated by transfecting HEK 293T cells with VLP-encoding
vector only. After 72 h, particles were isolated through ultracentrifugation. Subsequently,
5 µg/mL of HIV VLP or 5 µg/mL of multi-adjuvanted VLP were co-cultured with either
5 × 10' PBMC or THP-1 Dual cells in a 96-well plate format. In addition, THP-1 Dual
cells and PBMCs were stimulated with 1X PMA/Iono as a positive control. After 24 hours,
TNF-α concentration was determined in PBMC culture supernatant, whereas IRF
activation was determined by measuring Lucia luciferase activity from THP-1 Dual cell
culture supernatant. We observed that the multi adjuvanted VLPs induced significantly
more TNF-α from PBMCs compared to HIV VLPs (Fig 17A). In addition, multiadjuvanted VLPs induced significantly more IRF activation in THP-1 Dual cells compared
to HIV VLPs (Fig 17B). Collectively, this suggests that the packaged Multi-RNA adjuvant
could induce greater cellular reactivation than HIV VLPs.
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Figure 17. Multi Adjuvanted VLPs are more antigenic than HIV VLPs.
To determine the antigenic difference between adjuvanted VLPs and HIV VLPs, we
characterized IRF activation in THP-1 Dual cells, and TNF-α production in human PBMC
(n = 2). Specifically, we compared the antigenicity of Multi adjuvanted VLPs to HIV VLPs.
After culturing for 24 h, TNFα in PBMC culture supernatant was measured by ELISA (A).
IRF activation was measured by Lucia luciferase activity in THP-1 culture supernatant (B).
Bars are depicted as means ± SEM. *p<0.05, **p<0.005 using unpaired Student’s t tests.
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Chapter 4 – Discussion

4 Discussion
Since the seminal discovery during the early 1980’s, that HIV-1 was the etiological agent
behind the global AIDS pandemic, tens of millions of individuals have become infected
and an almost equal number of individuals have succumbed to the opportunistic infections
associated with the profound immuno-depletion. The introduction of antiretroviral therapy
has transformed the landscape of the pandemic from one of a certain death sentence to a
lifelong, treatment-manageable, chronic infection. However, there are several drawbacks
with the current position of the HIV epidemic including: 1) the dangerous rise of cART
resistant strains of HIV-1, beyond thresholds thought to be required to control HIV
infection at the community level174,175; 2) the massive expansion of HIV-1 infection rates
in numerous countries in Eastern Europe, Central Asia, and the Middle East (UNAIDS);
3) the less than expected declines in new infections within test and treat communities in
Africa176; 4) UNAIDS models predicting a rebound pandemic by 2030; 5) and the lack of
an efficacious vaccine in the foreseeable future. These factors collectively paint a bleak
forecast towards eradication efforts against HIV-1, or at the very least, efforts to control
and reduce infection rates. Therefore, there is an urgent need for innovation in potential
HIV-1 vaccine development that promotes long-lasting immunity for treatment of patients,
or perhaps a line of therapeutic strategies to either control the HIV pandemic or cure HIV
infected individuals.
To date, the only effective countermeasure to HIV infection is the administration of a daily
cART regimen, designed to block various stages of the HIV replication cycle. This daily
regimen is a life-long treatment strategy that must be administered without interruption to
prevent viral recrudescence and mitigate disease progression towards AIDS. The reason
behind the inability of cART to effect a cure in treated individuals rests in the ability of the
virus to, on rare occasions, reside in a dormant state within infected CD4 T cells. These
latently infected cells are the source of recrudescing virus during treatment interruption and
must be eliminated from the body in order to achieve a sterilizing cure. Over the last few
years, our research team has focused on the development of a novel HIV VLP immunotherapeutic designed to target latently infected cells for reactivation. To our knowledge,
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our group is the first to describe the targeted reactivation of the latent reservoir using HIV
VLP quasi-species (manuscript in submission). This approach stemmed from several key
findings in the literature that described the transcriptional reactivation of the latent
reservoir, within CD4 T cells, through stimulation of cells with HIV antigens and/or
peptides. Hence, we hypothesized that the latent reservoir might be preferentially housed
in CD4+ T cells with TCR specificity for HIV epitopes. Subsequent work detailing the
stimulation of CD4 T cells using VLP formulations, and how they led to latency reversal,
are now the subject of a manuscript under peer review. These non-infectious, genomeless
self-assembling nanoparticle structures, retains and expresses the native conformations
encompassing the viral quasi-species from five infected individuals. While the initial
previous work was carried out to investigate the potential latency reversing “shock”
delivered by the VLP, ongoing work evaluating the ability of the repetitive geometry
associated with repetitive ordered arrays of polypeptides that make up the constitution of
the VLPs is now being evaluated for their unique ability to prime naïve immune responses,
and also boost pre-existing immune responses in HIV-experienced individuals. This is
being development within the context of both prophylactic and therapeutic vaccine
strategies. The work presented in this thesis represents an alternative area of research
involving VLPs, where adjuvanting RNAs were designed and tested for encapsulation
within HIV particles. This was based on foundational work identifying HIV RNA as a
potential proinflammatory factor in our in vitro assays, and data suggesting that coformulating VLP with exogenous excipients such as ssRNA could augment latency
reversal. Therefore, we believe that the work presented is a significant step forward in the
design of a second generation of immune-therapeutic VLPs, with greater potential for
efficacious latency reversal and targeted immune activation.
HIV VLPs are essentially viral shells lacking HIV genetic information. This absence of a
viral genome renders the VLP non-infectious. We initially designed the latency reversal
formulation as VLPs with an eye on downstream advancement towards human clinical
trials. In that regard, the regulatory purity requirements by the European Medicines Agency
(EMA) and World Health Organization (WHO) have strict guidelines on nucleic acid
content in VLPs. For instance, a dose of 10ng DNA via the parenteral route or 100ug of
DNA via the oral route is accepted177. Accordingly, as opposed to developing a viral
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particle (VP) vaccine, which is easier and more cost effective, we developed VLPs to
diminish nucleic acid incorporation in our vaccine. Initially this seemed advantageous
when looking through the lens of a therapeutic vaccine for use in humans, as we would not
require additional downstream processes such as BenzonaseÒ treatment. However, as it
appears from the research presented in this thesis, in our attempt to develop a safe
therapeutic, by removing the packaged viral RNA, we have inadvertently reduced the
antigenicity and latency reversal properties of the HIV VLPs. The consequences of which
we hypothesized to be a lack of critical PAMPs for stimulation of innate PRRs and
subsequent production of pro-inflammatory mediators such as type-I interferons (T1 IFN)
and TNF-α.
To overcome these pitfalls associated with the reduced antigenicity and latency reversal of
genomeless VLPs, we investigated methods to efficiently adjuvant our VLPs using RNA
adjuvants. To do this we utilized a technology based on immunostimulatory, non-coding
RNAs. The overall aim of this was to test the hypothesis that exogenous or VLP-packaged
RNA can increase VLP antigenicity through intracellular recognition by cellular PRRs. If
so, the eventual aim was to test the 2nd generation VLP formulations (i.e. VLPs + packaged
RNA adjuvant) for their ability to augment HIV latency reversal. The work presented in
this thesis provides clear evidence that TLR agonism can augment both HIV VLP
antigenicity and the reversal of HIV latency in primary human cells. Initial screening of
TLR agonists alone, such as Pam3CSK4 and Flagellin (which agonize TLR1/2 and TLR5,
respectively) showed that latency reversal was achieved by Poly(I:C) (TLR3), Imiquimod
(TLR7) and ssRNA (TLR7/8 agonist). In fact, the extent of latency reversal using soluble
TLR ligands was found to comparable to latency reversal achieved by our latency reversing
VLP formulation. Interestingly, we found that co-administration of exogenous ssRNA, a
TLR7/8 ligand, with HIV VLPs was capable of augmenting latency reversal in primary
human CD4+ T cells. Despite the elevation in latency reversal being non-statistically
significant, we believe this additive effect to be a highly biologically significant result. This
is because, we now understand that although our VLP formulation is a more potent latency
reversal agent that clinically relevant HDACi and PKC agonists (manuscript under review),
it may not be reactivating the full proviral reservoir. This is a crucial antecedent, as all
activatable and replication competent HIV-1 must be purged from the body to achieve a
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viable cure. Even a single intact and activatable provirus that persists post-treatment,
increases the chance for viral recrudescence. Current estimates suggest that between 1 – 60
CD4+ T cells/million may harbor replication competent virus178. The blood samples we
have used in these studies are derived from donors, diagnosed and treated at acute stage of
infection, and are therefore expected to have a very small reservoir. This greatly contrasts
with the larger estimates of reservoir size in individuals treated at chronic stage of infection.
Therefore, any increase in latency reversal in these acute patient samples are noteworthy
as it signals more virus is being reactivated from what is a small reservoir.
Several groups have previously explored the latency reversal potential of TLR ligands and
provides context for the work presented in this thesis. For example, Novis et al. describe
the latency reversal potential of Pam3CSK4, a TLR1/2 agonist, within an in vitro TCM
cell culture model, and in cells isolated from aviremic HIV+ individuals. They suggest that
the activation of TLR1/2 culminates in activation of several transcription factors such as
NFAT, NF-κB, and AP-1, resulting in transactivation of proviral transcription.
Additionally, TLR5 agonism using flagellin has also been characterized to induce latency
reversal through the activation of NF-κB, resulting in viral gene expression in TCM cells
isolated from aviremic individuals. Interestingly, recent work by Li et al., describe the role
of toll-interacting protein (TOLLIP) on the maintenance of HIV latency. As a key cellular
adaptor protein, TOLLIP functions to negatively regulate TLR signaling. Their work
suggests that TOLLIP inhibits NF-κB-dependent transcription from the HIV-1 promotor
and may therefore contribute to HIV latency. In fact, in a latently infected Jurkat CD4+ T
cell model and CD4 TCM cells from infected individuals, TOLLIP knockdown promoted
proviral transcription. In addition, other groups have found that TLR7/8 and TLR9
activation can mediate latency reversal in a manner that is dependent on the production of
T1 IFNs by plasmacytoid DCs (pDC). During infection, these pDCs function as antiviral
sentinels, rapidly producing T1 IFNs in response to viral insults. This is mediated by viral
RNA detection by TLR7/8, resulting in the recruitment of MyD88 using the adaptor protein
AP3. Recruitment of MyD88 to endosomal compartments enables phosphorylation of
IRF7, resulting in the downstream production of T1 IFNs. A clinical trial for GS-9620, a
TLR7/8 agonist, is currently underway and previous studies in the non-human primate
model has already generated evidence that correlates the use of GS-9620 with reductions
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in viral reservoir size. In these NHP studies the animals showed strong upregulation of
IFN-stimulated gene expression following GS-9620 administration along with blips in
IFN-α within plasma within 24 h of administration. Hence, the ability of our RNA
adjuvants to stimulate via TLR7/8, upregulate NF-kB and IRF as well as stimulate IFN-a
production is noteworthy.
Within this thesis, we also provide evidence here that suggests virally packaged HIV RNA
is a significant contributor to HIV VP antigenicity and that the packaged RNA augments
the latency reversal potency of HIV VPs. Therefore, we hypothesized that an engineered
immunostimulatory RNA, capable of packaging into VLPs, may function to further
enhance the latency reversal properties of the VLP formulations. Our rationale behind
inclusion of a packaged RNA as opposed to the co-delivery of an adjuvanting RNA as an
exogenous excipient in the VLP formulation, was the need for a specific and targeted
approach to the latency reversal. We are cautious about using global immune cell
activators, as there is a significant risk of non-specifically stimulating CD4+ T cells. In
doing so, it would provide an abundance of target cells for which virus generated de novo
can infect and reseed the reservoir. Furthermore, due to the inherent instability of RNA
molecules, packaging an immunostimulatory RNA adjuvant into the protective HIV capsid
could prevent its degradation before it has time to get to its intended destination. Since HIV
can package its own genome using a stem-loop structure called the packaging element (Ψ),
we designed immunostimulatory RNAs that leverages Ψ to facilitate the preferential
packaging of the RNA adjuvants into HIV VLPs. This we hypothesized should enable the
RNA adjuvants to outcompete the packaging of cellular RNAs and the RNAs associated
with VLPs. The latter of which has an extensively mutated Ψ and has a significantly
diminished ability to be package158. The adjuvants we have designed contains “GC”-rich
motifs and “AU” rich motifs that have been previously shown to preferentially stimulate
TLR7 and TLR8171. In these previous studies, “GU”-rich 4-mer sequences such as
“GUUC” and “GUCC” were capable of potently activating TLR7/8 and IFN-α secretion,
whereas “AU”-rich 4-mer sequences such as “AUGU” and “UAUU” were shown to be
potent activators of TLR8 and TNF-α secretion. We therefore generated a Multi adjuvant
that contained both “AU” and “GC”-rich domains, a single “GC”-rich adjuvant that
promotes IFN-α responses, and a single “AU”-rich adjuvant to promote TNF-α responses.
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Before encapsidating the RNAs into VLPs, which we believe would take a substantial
amount of optimization, we condensed the candidate RNA adjuvants into lipoplexes to
stimulate our reporter cell line and human PBMC. To do this, we incubated the RNAs with
a polycationic lipid, DOTAP. This cationic lipid consists of a hydrophilic amine group
connected to a hydrophobic carbon backbone through a biodegradable ester linker region,
which greatly reduces associated toxicity due to its transient half-life in vivo. It is believed
that DOTAP interacts strongly with RNA through electrostatic interactions between the
hydrophilic trimethylammonium group and through hydrophobic interactions between the
aliphatic carbon backbone and GC-rich regions of RNAs. Internalization of DOTAP-RNA
complexes by cells has been shown to occur through several mechanisms, which include
dynamin-dependent endocytosis via clathrin coated pits and non-specific dynaminindependent endocytosis via macropinocytosis. Upon internalization and acidification of
endolysosomal compartments of the cell containing DOTAP-RNA complexes, the
interactions between the RNA and DOTAP molecules are overpowered by the reduction
in local pH. As a result, the RNA is liberated from the DOTAP molecule and is free to
activate cellular PRRs.
By using lipoplexed RNAs we show data that corroborates findings from Forsbach et al.,
that “GC”-rich RNA adjuvants induced the highest amount of IFN-α production, whereas
the “AU”-rich adjuvant induced the highest amount of TNF-α production in human
PBMCs. Notably, we did not observe an additive effect of TNF-α and IFN-α production
from the Multi adjuvant as a result of having both “AU”-rich and “GC”-rich sequences.
We believe this is in part, due to differences in secondary structure and sizes of the RNAs,
since the Multi adjuvant appeared to have shorter lengths of the immunostimulatory
domains. However, the role of RNA length on antigenicity has been an area of contention
because of the sequence length promiscuity of ORN binding sites in TLR7/8. However,
other RNA-sensing PRRs have size preferences. For instance, Melanoma DifferentiationAssociated protein 5 (MDA5), a cytosolic RNA sensor, prefers longer sequences. This is
because the RNA is used as a substrate to nucleate MDA5 filament formation. These
filaments act as docking structures for the activation of mitochondrial antiviral-signaling
protein (MAVS)179. In addition, the extensive secondary structure conferred by the
repetitive sequence motifs may allow cytosolic detection of these RNA adjuvants by RIG-
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I. Interestingly, recent work has elucidated a family of short stem loop RNAs (SLR) that
induces potent IFN responses through the specific activation of RIG-I. These SLRs are
comprised of 10-14 nucleotides, and the minimal nature of these ligands suggest that
multimerization of RIG-I on RNA is not required, unlike MDA5 which requires
multimerization to promote MAVS signaling180. Therefore, it is plausible that a more
careful examination of the size and secondary structures of adjuvanting RNAs could help
define its immunostimulatory potential. In addition, studies evaluating the RNA adjuvants
in knock-out mice will help implicate specific molecular pathways triggered by these
RNAs.
Since our engineered immunostimulatory RNAs displayed great promise as lipoplexed
adjuvants, we also evaluated them as an exogenous adjuvant in our VLP formulations. As
shown, the co-administration of our engineered adjuvants with VLPs did significantly
increase the antigenicity of the VLPs in cell lines as measured by NF-κB and IRF
activation. Our evidence also suggests that the exogenous RNA adjuvants increase the
antigenicity of co-administered VLPs, to a greater extent than HIV RNA in VPs. To
elucidate a mechanism through which the RNA adjuvants exert their antigenic effects, we
used two ODNs (IRS-661 and IRS-954) that contain sequence motifs known to
competitively inhibit TLR7 and 8 activation. Although the mechanism of inhibition by
these ODNs are poorly understood, evidence based on the pattern of specificity suggest
that the inhibition is mediated through competitive antagonism181. As an alternative to the
ODNs, we also used chloroquine, which is a lysosomotropic compound that inhibits
endosomal acidification. Unlike IRS-661 and 954, the mechanism of chloroquine is wellcharacterized. Initially, chloroquine-mediated inhibition of endosomal acidification was
thought to preclude TLR activation since a low endosomal pH was a key antecedent for
endosomal TLR ligation and signaling182. However, there is now considerable evidence
that suggests the underlying cause of inhibition is independent of endosomal acidification.
Rather, the inhibitory effect of chloroquine stems from its high binding affinity to RNA.
In doing so, chloroquine occludes moieties that normally confer binding to endosomal
TLRs183. Our data shows that IRF activation can be inhibited by all three agents, whereas
NF-κB activation could only be inhibited by chloroquine. The inability to attenuate NF-κB
activation using IRS-661 and IRS-954 suggests that other innate immune recognition
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pathways‒independent of endosomal TLRs‒are also being activated. Future studies must
be conducted to further characterize the cross-talk across pathways of RNA recognition,
because these details are still obscure.
It is important to delineate the difference between the co-administration of exogenous RNA
adjuvant and VLPs with the co-delivery of packaged RNA adjuvant in VLPs. This is
because in the latter case, VLPs with encapsidated RNA are likely to both end up in the
same endosomal compartment within the same cell. From a structural perspective, the
former approach does not consolidate the RNA adjuvant and VLP into a single nanoparticle
structure, whereas the latter approach utilizes ψ to package the RNA adjuvant inside the
HIV VLP, ensuring that HIV VLP and RNA adjuvant is delivered to cells concurrently.
Therefore, co-delivery does not guarantee the localization of the RNA adjuvant and HIV
VLP to the same endosomal compartment, which is critical for enacting a durable immune
response for maximal latency reversal potential. Several studies have shown that the
“entrapment” of antigens into a single polymeric structure synergizes the antigenicity of
its individual components by enabling the cross-presentation of antigens via MHC-I and
MHC-II. In fact, this is one of the major reasons why conjugation of adjuvants and antigens,
or adsorption of antigens onto adjuvants is done. Since the antigenicity of our RNA
adjuvants were determined by co-administration of HIV VLP with a liposomal complex of
exogenous RNA adjuvant, these results may underestimate the true antigenic capacity of
the RNA adjuvants. We only administered the RNA adjuvant as an exogenous excipient in
the VLP formulation to accelerate the investigative process by enabling us to quickly
screen the candidate RNAs for their adjuvant activity. This also enabled us to avoid
complications surrounding efficient production of VLPs containing packaged RNA using
dual plasmid transfection methods.
While the work outlined in the thesis emphasizes the importance of adjuvanting the VLPs
in latency reversal studies, it also alludes to the natural ability of the HIV genome to trigger
latency reversal. This was a surprise finding as HIV-1 is thought to be “hardwired” to form
a transcriptionally silent, latent reservoir within cells, with what has been previously
described as a virally-encoded program behind the latency109. Moreover, Brodin et al., has
recently shown that within infected individuals, the virus that was replicating immeditaley
prior to suppressive cART may be the virus that predominates within the HIV-1 DNA
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reservoir184, while Abrahams et al., show that the replication-competent latent reservoir is
primarily established near the time of cART initiation185. Of course these are important
points of discussion which cannot be easily answered within the scope of this thesis.
In summary, the work presented in this thesis offers evidence that implicates exogenous
or virally packaged RNA in enhancing VLP antigenicity and latency reversal ability. In
light of this, we also describe the engineering of immunostimulatory RNAs that can be
packaged into VLPs and further augment antigenicity.
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Appendices
Primer Name

Sequence (5’ à 3’)

5’ LTRPA

CCCACTGCTTAAGCCTCAATAAAGC

GagR

CTTACTTTTGTTTTGCTCTTC

GagF

GGAGCTAGAACGATTCGCAG

B1F

ATCCGGAGGCACGGGGCTCAAAGCCGCGAC

B1R

GTCGCGGCTTTGAGCCCCGTGCCTCCGGAT

B2F

ACGACGGCTCTCGGCCGGTAACAGTAACCC

B2R

GGGTTACTGTTACCGGCCGAGAGCCGTCGT

B3F

CTGCCCTGGTGAGCGCCATCAGCAACCCGA

B3R

TCGGGTTGCTGATGGCGCTCACCAGGGCAG

B4F

ATACGTGGCATTTCAGGAGGCGGCCGGAGG

B4R

CCTCCGGCCGCCTCCTGAAATGCCACGTAT

Table 1. Primers used in this thesis
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